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I Abbreviations 
 
5hmC 5-hydroxymethylcytosine 
AD Alcohol dependence 
AP-1 Activator protein 1 
BPD Borderline personality disorder 
CBT Cognitive behavioral therapy 
CGI CpG island 
CpG Cytosine-phosphate-guanine 
CPT Cell preparation tube 
DBT Dialectical behavior therapy 
DMR Differentially methylated region 
DNA Deoxyribonucleic acid 
DNMT DNA methyltransferase 
DSM Diagnostic and Statistical Manual of Mental Disorders 
EDTA Ethylenediaminetetraacetic acid 
EWAS Epigenome-wide association study 
FACS Fluorescence-activated cell sorting 
FDR False discovery rate, Benjamini-Hochberg adjusted 
GABA γ-aminobutyric acid 
GWAS Genome-wide association studies 
MBD Methyl-CpG-binding domain 
MBT Mentalization-based therapy 
miRNA microRNA 
NK Natural killer (cells) 
NMDA N-methyl-D-aspartate 
PBMC Peripheral blood mononuclear cell 
PCR Polymerase chain reaction 
qPCR Quantitative polymerase chain reaction 
RNAi RNA interference 
SAM S-Adenosyl Methionine 
SNP Single-nucleotide polymorphism 
sRNA small RNA 
TET Ten-eleven translocation 
TFP Transference-focused psychotherapy 
TNF Tumor necrosis factor 
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III Summary 
Alcohol dependence and borderline personality disorder are two complex psychiatric 
disorders. Although studies indicate a high genetic heritability of 40 – 60% for these 
diseases, the remaining variability still has to be investigated. One major contributor 
to this “missing heritability” is thought to be explained by epigenetics. Epigenetics 
includes a number of pathways that ultimately alter gene expression. The most 
studied mechanism is DNA methylation, which occurs on cytosines in the context of 
cytosine-guanine dinucleotides. Methylation of DNA can act as steric hindrance and, 
by recruiting further proteins, promote histone deacetylation and additional de novo 
DNA methylation usually resulting in decreased gene expression. 
Here, we examined epigenome-wide T cell DNA methylation in alcohol dependent 
patients compared to healthy controls, as well as before and after an alcohol 
treatment. We found that global DNA methylation was decreased in patients 
compared to controls, but reverted back after the alcohol treatment, leading to the 
loss of significant differences compared to controls. In addition, we identified unique 
sets of differentially methylated sites and genes between patients and controls and 
between patients pre- and posttreatment. From these unique sets, we further 
identified sites and genes which changed during the alcohol treatment. To verify our 
epigenome-wide results, we validated our top-ranked hits by pyrosequencing and, 
additionally, aimed to replicate them in an independent cohort and in whole blood 
DNA. The fact that we found both SRPK3 and HECW2 differentially methylated in T 
cells and in whole blood supports their potential value as novel blood-based 
biomarkers for alcohol dependence. 
In addition, we investigated DNA methylation of APBA3 and MCF2 in borderline 
personality disorder patients compared to healthy controls as well as before and after 
a 12-week dialectical behavior therapy. Although we did not detect statistically 
significant differences in DNA methylation between patients and controls, we found 
that both genes were higher methylated pre-treatment in patients responding to 
therapy compared to non-responders. This indicates that APBA3 and MCF2 DNA 
methylation might be potential candidates of novel predictive epigenetic biomarkers 
for dialectical behavior therapy outcome. 
However, further studies are needed to replicate these results in independent cohorts 
and to decipher the role these genes might play in the respective disease. 
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IV Zusammenfassung 
Zu den komplexen psychiatrischen Erkrankungen zählen unter anderem 
Alkoholabhängigkeit und die Borderline Persönlichkeitsstörung. Beide Erkrankungen 
haben eine vergleichsweise hohe genetische Heritabilität von 40 – 60%. Die 
verbleibende Variabilität kann unter anderem durch die Epigenetik erklärt werden. 
Epigenetik umfasst mehrere molekulare Mechanismen, darunter die DNA 
Methylierung. Diese enzymatische Modifikation geschieht an Cytosinen, die in einem 
Cytosin-Guanin-Dinukleotid präsent sind. Methylierte Cytosine können sowohl als 
direkte sterische Hinderung von Transkriptionsfaktoren agieren, als auch durch die 
Rekrutierung weiterer Proteine die Acetlyierung von Histonen und die de novo 
Methylierung der DNA bewirken. Diese Modifikationen führen in der Regel zu einer 
verminderten Genexpression. 
In dieser Arbeit wurde die epigenomweite DNA Methylierung in T-Zellen zwischen 
alkoholabhängigen Patienten und gesunden Kontrollen sowie zwischen den 
Patienten vor und nach einer Alkoholentzugstherapie untersucht. Die epigenomweite 
Methylierung der Patienten war im Vergleich zu den Kontrollen signifikant niedriger, 
glich sich jedoch nach der Therapie den Werten der Kontrollen an. Des Weiteren 
wurden etliche signifikant unterschiedlich methylierte Sites und Gene zwischen 
Patienten und Kontrollen und zwischen Kontrollen vor und nach dem Entzug 
gefunden. Um die epigenomweiten Ergebnisse zu verifizieren, wurden vier 
signifikante Sites durch Pyrosequenzierung validiert und in einer weiteren, 
unabhängigen Kohorte repliziert. Durch die weitere Replizierung in Vollblut könnten 
die Methylierung von SRPK3 und HECW2 künftig potentiell als neue, epigenetische 
Biomarker für Alkoholabhängigkeit dienen. 
Zusätzlich wurde die Methylierung von APBA3 und MCF2 in Patienten mit Borderline 
Persönlichkeitsstörung untersucht. Im Vergleich zwischen Patienten und Kontrollen 
fanden sich keine signifikanten Unterschiede. Wurden die Patienten jedoch nach der 
dialektisch-behavioralen Therapie in eine Responder und eine Non-Responder 
Gruppe eingeteilt, war die Methylierung beider Gene vor der Therapie bei den 
Respondern signifikant erhöht.  Somit könnte die Methylierung von APBA3 und 
MCF2 als prädiktiver Biomarker für den Therapieerfolg der dialektisch-behavioralen 
Therapie geeignet sein. 
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Weitere Studien mit größeren und unabhängigen Kohorten werden jedoch benötigt, 
um diese Ergebnisse zu validieren und replizieren und die Rolle dieser Gene in den 
jeweiligen Erkrankungen zu untersuchen. 
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1 Introduction 
1.1 The burden of alcohol dependence 
Alcohol dependence (AD) is a very complex and severe disorder that affects a total of 
208 million people worldwide, not including a potentially high estimated number of 
unreported cases. Approximately 3.3 million deaths each year are caused by alcohol 
abuse [1]. In 2015, a total of approximately 327,000 patients in Germany were 
enrolled in inpatient treatment programs as a result of their alcohol abuse. Alcohol 
abuse is not a problem solely adults are confronted with: 22,000 of the above 
mentioned cases were patients between the age of ten and 19 [2]. Although these 
numbers are high and mental and behavioral disorders caused by alcohol abuse are, 
after cardiac insufficiency, the second ranked reason for an inpatient treatment in 
Germany, the impact of AD has been underestimated in the past and is still 
underestimated today [3]. 
To receive a diagnosis of AD, three or more of the seven criteria listed in Table 1 
must have been met in the past twelve months according to the Diagnostic and 
Statistical Manual of Mental Disorders DSM-IV [4]. 
Table 1: Criterions of alcohol dependence according to the DSM-IV [4]. 
Criterion Description 
Criterion 1 Need for markedly increased amounts of alcohol to achieve intoxication or 
desired effect; or markedly diminished effect with continued use of the same 
amount of alcohol 
Criterion 2 The characteristic withdrawal syndrome for alcohol; or drinking (or using a 
closely related substance) to relieve or avoid withdrawal symptoms 
Criterion 3 Drinking in larger amounts or over a longer period than intended 
Criterion 4 Persistent desire or one or more unsuccessful efforts to cut down or control 
drinking 
Criterion 5 Important social, occupational, or recreational activities given up or reduced 
because of drinking 
Criterion 6 A great deal of time spent in activities necessary to obtain, to use, or to 
recover from the effects of drinking 
Criterion 7 Continued drinking despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to be caused or exacerbated 
by drinking 
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To date, the underlying neurobiological mechanisms of AD are only insufficiently 
understood. Studies indicate a genetic heritability of 40 – 60% while environmental 
and stochastic effects account for the remaining variability [5, 6]. Regarding genetic 
factors that contribute to the risk of developing AD, it has been controversially 
discussed if the age of onset of drinking also is involved in the development of AD [7, 
8]. However, it has been shown that with decreasing age at first drink, the risk for AD 
symptoms increased and that the age of first drink facilitates the expression of genes 
associated with vulnerability to AD symptoms [7].  
AD is considered both a physical and psychological addiction [1, 9]. The physical 
addiction is experienced as increased tolerance against alcohol and physical 
symptoms when stopping or reducing alcohol intake, such as nausea, seizures, 
headache, sweating and the restless leg syndrome, among many others. Primarily, 
the γ-aminobutyric acid (GABA) and N-methyl-D-aspartate (NMDA) receptors play a 
key role in mediating various aspects of alcohol dependence syndromes. Specifically, 
the increased NMDA receptor activity and the decreased mesolimbic dopaminergic 
function due to chronic alcohol consumption are believed to contribute to the 
withdrawal symptoms and to the compulsion to drink alcohol [10]. The psychological 
addiction is presenting itself as intense craving, feelings of anxiety, denial of 
problems caused by drinking alcohol, depression, and others [11, 12]. 
Because of the psychological and physiological impact of AD, good treatment options 
are required. The aim of AD treatments is to alleviate withdrawal symptoms (with 
drug therapy) and to deal with underlying psychological problems as well as to 
prevent relapse of the patients through psychotherapy [13-15]. At the Department of 
Psychiatry and Psychotherapy, Tuebingen, two inpatient alcohol treatment programs 
are offered, lasting for either three or six weeks. If necessary, clomethiazole is 
administered at the beginning of either treatment. By acting as positive allosteric 
modulator of the GABAA receptor, clomethiazole enhances the effects of the 
inhibitory neurotransmitter GABA and clomethiazole treatment therefore helps to 
reduce withdrawal symptoms and avoid delirium tremens [16]. Patients participate in 
group therapy with a focus on psychoeducational training and attend physiotherapy 
and occupational therapy with the aim of returning to a normal life-style within a short 
time period. The six-week program consists of additional individual psychotherapy 
and a one year post-treatment outpatient therapy to prevent fast relapse. However, in 
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general, drop-out rates are high and long-lasting success is limited, as shown by high 
relapse rates and repeated clinical visits of affected patients [11]. 
 
1.2 Borderline personality disorder 
Borderline personality disorder (BPD) is a complex and severe disorder which is 
characterized by a high risk of suicide, severe functional impairments and unstable 
relationships with other people [17, 18]. Prevalence for BPD in the general population 
is about 0.5 – 5.9% (median 2.8%) and 15 – 25% in clinical settings [19, 20]. BPD 
patients very often suffer from comorbidities such as depression, anxiety disorders, 
eating disorders and substance abuse [17]. 
A number of factors may contribute to the onset of BPD. The estimated heritability of 
BPD is around 40% [21, 22]. Biological and psychological factors (such as 
neurobiological dysfunctions or personality traits) may influence the development of 
the disorder, together with environmental factors such as adverse childhood 
experiences [17, 23]. 
The efficacy of several treatment models, including cognitive behavioral therapy 
(CBT), dialectical behavior therapy (DBT), transference-focused psychotherapy 
(TFP) and mentalization-based therapy (MBT), have been studied intensively in the 
past years [24]. DBT, developed by Marsha Linehan [25], focuses on the reduction of 
suicide risk and behavior antagonizing an inpatient treatment [26] and is exercised as 
a twelve-week inpatient treatment program at the Clinic of Psychiatry and 
Psychotherapy in Tuebingen. 
 
1.3 Challenges of current research 
One of the conclusions that emerged from the Human Genome Project was the 
phenomenon of “missing heritability”: Although candidate-gene driven studies 
showed strong associations of genetic variants with psychiatric diseases, they could 
not solely account for their heritability [27]. In addition, genome-wide association 
studies (GWAS) could only replicate a small number of these associations, 
implicating that there might be a high number of false-positive findings [28]. Vice 
versa, significant findings in GWAS could also rarely be verified in subsequent 
studies. This led to two conclusions: First, replication is of paramount importance to 
prevent false-positive findings. Second, other mechanisms in addition to genetic 
Introduction 
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heredity are likely to play a role in the development of those complex diseases. In 
recent years, evidence has emerged that environmental factors play a major role in 
various psychiatric disorders, among them AD and BPD [29-31], and that epigenetics 
may account for a significant fraction of the “missing heritability” [32]. 
Another major challenge of current research is to find disease-specific biomarkers 
[33]. Biomarkers have a broad range of application from staging diseases to 
diagnosis to monitoring disease or treatment progress [34]. They also can be used to 
identify patients more likely to benefit from one or another treatment and, therefore, 
support the selection of optimal treatment options [35]. These so called predictive or 
prognostic biomarkers are commonly accepted and used in cancer treatment [36]. 
Compared to the field of oncology, the use of biomarkers for psychiatric disorders is 
still very limited. Although a number of biomarkers exist for psychiatric disorders, 
including Alzheimers’ disease, major depression and AD [37-39], more research is 
needed to cover a greater range of disorders and to determine the value of specific 
biomarkers in validation and replication studies. 
 
1.4 Epigenetics 
Epigenetics was first defined by Conrad Waddington in 1942 as “the branch of 
biology which studies the causal interactions between genes and their products 
which bring the phenotype into being” [40] and later revised to the following: “An 
epigenetic trait is a stably heritable phenotype resulting from changes in a 
chromosome without alterations in the DNA sequence” [41].  
Research in epigenetics nowadays comprises mostly the impact of environmental 
factors on DNA methylation, histone modification and the role of diverse RNA 
transcripts, such as microRNAs (miRNA) [42], double-stranded interfering RNA 
(RNAi) and small, regulatory RNAs (sRNA) [43].  
Epigenetics had its breakthrough in cancer research, where epigenetic alterations 
were found to have a vast impact on the etiopathology and could even be one of the 
major mechanisms driving the development of the disease [44, 45]. A large number 
of candidate genes were found to be epigenetically altered, mainly leading to 
reduced expression of DNA repair genes [46, 47]. Epigenetic research has already 
found its way into modern medicine: For certain types of cancer, treatment with DNA 
methyltransferase (DNMT) inhibitors, namely Azacitidine and Decitabine [48, 49], can 
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improve patient outcomes. By acting as cytidine homolog, they indirectly cause a 
hypomethylating of candidate gene promoters leading to a reactivation of the cellular 
tumor defense [50, 51]. Since both drugs have a general, nondirectional effect, to 
date they can only be applied for certain types of cancer and bear considerable side-
effects [52, 53]. However, very recently, targeted DNA demethylation has proven 
possible in vivo [54, 55], laying the foundations for future applications in cancer 
treatment and beyond. 
The epigenetic pathway can be divided into three steps (Figure 1): First, a so called 
“epigenator” functions as the signal for epigenetic changes. Epigenators can be 
differentiation signals as well as environmental or lifestyle factors, such as 
temperature, diet, exercise etc. [56]. Second, “epigenetic initiators” such as non-
coding RNAs or DNA binding factors transduce the signal onto the DNA in the cell 
nucleus. In a third step, the actual epigenetic changes are implemented by histone 
and DNA modifications, which are the “epigenetic maintainers” [41]. 
 
Figure 1: The epigenetic pathway.  
Starting with the “epigenator”, the signal for inducing epigenetic changes, they are conveyed by the 
“epigenetic initiator”. The actual changes are enforced by histone and DNA modifiers, i.e. DNA 
methyltransferases (“epigenetic maintainer”). From Berger, S.L. et al., Genes Dev, 2009 [41].  
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The most common modifications are DNA methylation and histone acetylation, 
methylation and phosphorylation. Depending on the type of modification, the resulting 
changes in gene transcription can be very different: In general, DNA methylation and 
histone deacetylation preserve DNA in a dense, inaccessible state (heterochromatin), 
which leads to reduced gene transcription. Unmethylated DNA and histone 
acetylation promote an open, accessible state of the DNA (euchromatin) and lead to 
increased gene transcription [57-59]. Histone methylation and phosphorylation can 
lead to either a heterochromatin or euchromatin DNA state, which highly depends on 
the exact position of the modification [60, 61]. Numerous studies show that DNA 
methylation and histone modification influence each other [62-64]. However, these 
general rules do not always apply and recent studies show that the relationship 
between DNA methylation and gene expression is far more complex than first 
imagined and involves a number of additional variables [65, 66]. 
Initially, it was believed that after remodeling in early development, DNA methylation 
is irreversible [67]. However, by showing that these alterations could change over a 
lifetime and adapt to different environmental factors, epigenetics became one of the 
prime research areas in the field [68, 69]. 
 
1.4.1 DNA methylation 
DNA methylation is one of the best studied epigenetic mechanisms. Hereby, a 
cytosine is methylated at the fifth position in the pyrimidine ring, forming 5-
methylcytosine [70]. This reaction is catalyzed by DNA methyltransferases (DNMTs), 
which depend on S-Adenosyl methionine (SAM) as methyl group donor [71] (Figure 
2).  
DNA can be methylated de novo or the existing methylation pattern can be 
maintained, which is a crucial process during cell division [72]. DNA methylation 
usually only occurs on cytosines in the context of cytosine-phosphate-guanine (CpG) 
dinucleotides, which are not evenly distributed throughout the genome, but 
condensed in regions called CpG islands (CGI) [66]. These CGIs are prominently 
found in gene promoter regions and generally, methylated CGIs are associated with 
silencing of gene transcription [73]. Non-cytosine DNA methylation, namely adenine 
methylation, has been reported, but research in this field has just begun and the 
effects remain unclear to date [74]. 
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Figure 2: Methylation of cytosine catalyzed by DNA methyltransferases. 
A cytosine (top left) in a CpG context can be methylated at the carbon 5 position by DNA 
methyltransferases to form 5-methylcytosine (top right). DNA methyltransferases require S-Adenosyl 
methionine as methyl group donor (center). From Ahmed, H., Biomark Cancer, 2010 [71]. 
 
Decreased gene transcription through methylated cytosines is mediated by several 
pathways: First, the addition of a methyl group in transcription factor binding sites can 
act as steric hindrance [75]. Second, and more importantly, proteins with methyl-
CpG-binding domains (MBD) can bind to methylated DNA regions and actively 
promote a heterochromatin state, modify histones by deacetylation and coordinate de 
novo DNA methylation by recruiting DNMTs [76]. 
It has been found that the position of the methylated cytosine in respect to the gene 
location plays an important role. It is widely accepted that DNA methylation in the 
promoter region of a gene leads to less expression, whereas methylation inside the 
gene body can lead to enhanced expression of the respective gene [77]. Although 
methylation in promoter-adjacent regions has proven to be functionally important, 
further studies are needed to evaluate its role [66]. 
Since DNA methylation is a reversible process, methyl groups can be removed from 
cytosines. This process can occur either passively, by missing re-methylating of the 
DNA during replication by DNMT1, or actively catalyzed by enzymes [78]. Ten-eleven 
translocation (TET) proteins play a major role in this process: They catalyze the 
oxidation of 5-methylcytosine, leading to 5-hydroxymethylcytosine (5hmC). Multiple 
pathways have been shown to contribute to the further demethylation pathway. For 
example, 5hmC can be directly deaminated enzymatically, forming unmodified 
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cytosine [79]. It can also be iteratively oxidized by TET enzymes, leading to 5-
formylcytosine and 5-carboxylcytosine [80], which in turn can be excised from the 
DNA [81]. However, only little is known about the regulation of the active 
demethylation process and how specific loci are demethylated, requiring further 
investigation. 
 
1.4.2 Factors driving differential DNA methylation 
Differential DNA methylation is driven by several factors. The main focus of many 
studies is to find disease-related differential methylation by comparing a disease-
carrying cohort with a healthy cohort. 
However, there are several confounding factors which can result in differential DNA 
methylation and are not always addressed in scientific studies [65, 82]. First, DNA 
methylation is tissue-specific, meaning that tissue from different origin can be 
differentially methylated [83]. Second, even within a certain tissue, DNA methylation 
is still cell type-specific, meaning that variations in cellular composition of samples 
can confound the analysis of DNA methylation. This is especially and unfortunately 
true for whole blood, which is commonly used for DNA methylation studies [84].  
Third, it is well known that ethnicity [85], sex [86] and age [87] influence DNA 
methylation. Most obvious differences between males and females include, for 
example, that only females show hypermethylation of gene promoters on the X 
chromosome [88]. Also, higher age was found to be correlated with decreased DNA 
methylation [89]. Further, numerous studies show that nicotine consumption can also 
have a strong impact on DNA methylation. In fact, the association of smoking and 
DNA methylation is one of the most studied relations in epigenetic studies and wide-
spread changes in the DNA methylation patterns due to smoking have been shown, 
which were partly reversed after cessation [90]. A study by Besingi and Johansson 
suggests that differential DNA methylation is not caused by the basic components of 
tobacco, but from its burnt products, such as arsenic [91]. 
When conducting DNA methylation studies, these factors should all be taken into 
account and matched to the best of one’s ability to avoid confounding effects. Since 
high-throughput methods such as Illumina’s 450K beadchip array have become 
popular in recent years, additional caution is necessary to avoid technical variability, 
such as batch and chip effects. 
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1.5 DNA methylation and alcohol dependence 
Several publications show a major impact of AD on DNA methylation. While 
candidate-gene driven studies focus on specific sites or genes, epigenome-wide 
association studies (EWAS) present a hypothesis-free approach to measure a large 
number of single CpG sites at once, depending on the method and platform used. 
However, studies so far have found partly conflicting results. 
 
1.5.1 Global DNA methylation studies 
Several studies have examined global DNA methylation in AD patients. Within these, 
three different methodologies were used: I) Endonuclease digestion, II) 
pyrosequencing of Alu and / or LINE-1 and III) microarray assays following 
methylated DNA immunoprecipitation. The method most commonly used, 
pyrosequencing of Alu and / or LINE-1, enables to estimate global DNA methylation 
by sequencing repetitive elements [92]. LINE-1 (long interspersed nuclear elements) 
belongs to the family of transposable elements and comprises about 17% of the 
human genome [93]. Similarly, Alu, which belongs to the group of small interspersed 
nuclear elements, is the most abundant transposable element with over 1 million 
copies throughout the genome [94]. Studies using this method have found conflicting 
results: One study found global DNA hypermethylation in AD patients [95], another 
one an inverse correlation of higher alcohol consumption resulting in lower global 
DNA methylation [96]. A third study did not find any effect of AD on global DNA 
methylation [85]. Earlier studies hypothesized that due to the higher homocysteine 
levels in AD patients, global DNA methylation patterns should be elevated [97]. 
However, a study comprising a large cohort did not confirm these findings [98]. 
Another hypothesis postulates that global DNA hypomethylation in AD patients is 
attributed to the lack of methionine adenosyl transferase regulation [99, 100]. These 
controversial results lead to the conclusion that further studies are needed to 
understand the impact of AD on global DNA methylation. 
 
1.5.2 Candidate-gene driven studies 
Taken together, 12 candidate genes have been studied for their associations with AD 
or alcohol abuse: ANP, AVP, GRIN2B, HERP, MAOA, OPRM1, Orexin A, POMC, 
SLC6A3, SLC6A4, SNCA [29] and GDAP1 as part of this work [101]. The most 
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prominently studied gene, SLC6A3, the solute carrier family 6 member 3 encodes for 
a dopamine transporter and was analyzed in four different studies. Two studies 
showed hypermethylation in the promoter region of this gene [102, 103], while 
another two studies could not detect any differences between controls and AD 
patients [104, 105]. The methylation status of GRIN2B [106], POMC [107] and MAOA 
[108] did not show significant changes, but correlated with symptoms of AD such as 
craving or symptom counts. The majority of the analyzed genes exert functions in 
neurotransmission. 
All the above-mentioned studies have several limitations: A broad variety of different 
methodologies (i.e. RT-PCR, pyrosequencing, bisulfite sequencing, mass 
spectrometry etc.) were used, hindering comparability. Additionally, the study 
material in most cases was peripheral whole blood, which is not optimal due to its 
multi-cellular composition. Also, not all studies had closely matched patient and 
control groups. As discussed earlier, this is of paramount importance to gain 
meaningful results which are not confounded by factors such as age, sex, ethnicity 
and smoking behavior. Furthermore, not all studies were able to validate or replicate 
their results. This concludes to the fact that more work and, most of all, closely-
matched cohorts are needed to clearly decipher the implication and role of these 
genes in AD as learning more about these genes may also lead to a better 
understanding of AD. In addition, a suitable epigenetic biomarker for the disease is 
missing to date. In clinical settings, biomarkers could facilitate and improve treatment 
tremendously. However, the mentioned studies were not able to successfully 
introduce a novel epigenetic biomarker for AD. To circumvent the above-mentioned 
limitations and to have a hypothesis-free approach, in this work we conducted an 
EWAS aiming to detect novel differentially methylated sites and regions. 
 
1.5.3 Epigenome-wide association studies 
In addition to candidate-gene driven studies, a few EWAS have been conducted to 
date and have found widespread AD-associated DNAm differences. Differential 
methylation at 1,710 sites in lymphocytes of alcohol dependent patients [109] as well 
as 77 differentially methylated regions (DMRs) associated with 62 genes were 
identified in whole blood samples from discordant monozygotic twin pairs [110]. An 
additional genome-wide study using postmortem precuneus brain tissue samples 
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identified a total of 1,046 differentially methylated sites in AD patients compared to 
healthy controls, of which 432 displayed significant cross-tissue correlation between 
matched brain and buccal samples [111]. 
Philibert and colleagues were the first to assess DNA methylation alterations in 
peripheral blood mononuclear cells (PBMCs) of AD patients before and after 
participating in a short-term alcohol treatment program [112]. Comparing patients 
before treatment to healthy controls, they reported differential methylation at 56 sites. 
Although no significant DNAm differences were observed in patients pre- and post-
treatment, 49 of the 56 differential sites reverted to levels similar to controls in 
patients after treatment [112]. However, this study had a few limitations: Both male 
and female study participants were included, as well as participants with a different 
ethnic background. More severely, smoking behavior between patients and controls 
was not matched. As pointed out earlier, matching patient and control groups is 
essential, since only a closely matched cohort will reveal results that represent 
changes specific to the investigated disease. 
Although all these previous EWAS identified a multitude of AD-associated 
differentially methylated sites, they did not account for cell type heterogeneity in their 
analyses, thereby confounding and limiting the comparability of their findings. Most 
recently, a study involving 13,317 participants from 13 distinct cohorts reported 
hundreds of AD-associated differentially methylated sites in DNAm profiles of 
monocytes and whole blood, which was adjusted for cell composition [113]. This 
study was the first one to account for cellular heterogeneity in whole blood samples 
and found a large number of differentially methylated genes and regions, including 
the γ-Aminobutyric acid-A receptor delta and γ-aminobutyric acid B receptor subunit 
1. The limited amount of the studies and their controversial results show the need for 
more research in this field. Additionally, validation and replication of previous findings 
is of great importance. 
 
1.6 DNA methylation and borderline personality disorder 
Several studies have shown an association between BPD and differential DNA 
methylation of candidate genes. Using pyrosequencing, a study found differential 
DNA methylation in HTR2A, NR3C1, MAOA, MAOB and soluble COMT (S-COMT). 
However, the observed effects were comparatively small, ranging from 0.8% (5-
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hydroxytryptamine receptor 2A, HTR2A) to 1.8% methylation difference in the 
glucocorticoid receptor gene NR3C1 [30]. Another study confirmed the association of 
BPD with the glucocorticoid receptor gene and found that childhood abuse and its 
severity positively correlated with NR3C1 methylation [114]. In addition, differential 
DNA methylation of the second subunit of the serotonin receptor gene (HTR3A) 
[115], as well as hypermethylation of the brain-derived neurotrophic factor (BDNF) 
gene were found to be associated with BPD [116]. Most recently, an association 
between BPD and the DNA methylation of rDNA and PRIMA1 was shown [117]. 
Only one EWAS has been conducted for BPD so far: Comparing a cohort of 24 
female BPD patients and 11 healthy controls, Teschler and colleagues found APBA2, 
APBA3, KCNQ1, MCF2 and NINJ2 to be differentially methylated and could validate 
the findings of APBA3, MCF2 and NINJ2 by pyrosequencing [31].  
As with the previously mentioned findings for AD, a suitable biomarker measuring 
treatment success has not yet been found. Since BPD treatment is very time 
intensive, finding a predictive biomarker for treatment outcome would greatly benefit 
both patients and clinics. 
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2 Aim of the study 
Although the role of DNA methylation and other epigenetic markers in alcohol 
dependence (AD) and borderline personality disorders (BPD) has been investigated 
in a number of studies, these had several limitations and many unanswered 
questions remain. Previous studies did not have closely matched patient and control 
cohorts. Furthermore, DNA methylation levels reported in previous studies were 
examined in different tissue and cell types, thereby adding confounding factors and 
limiting comparability. In addition, changes from pre- to post-treatment were 
investigated in only one study each for AD [112] and BPD combined with dialectic 
behavior therapy [116].  
The aim of this work is to identify epigenetically altered genes associated with these 
two disorders. For the study of AD and early recovery, we performed an EWAS of 
CD3+ T cell DNA methylation of 23 healthy controls compared to 24 alcohol 
dependent patients on Illumina’s HumanMethylation 450K beadchip array platform. 
We thereby emphasized on matching our groups to the best of our ability to exclude 
confounding factors. Furthermore, we compared the 24 patients before and after a 3-
week alcohol treatment program at the Department of Psychiatry and Psychotherapy 
in Tuebingen to identify associations related to early recovery of AD. In contrast to 
the majority of previous studies, we validated our top-ranked hits by pyrosequencing 
and replicated the top findings from our EWAS analyses in T cell DNA in a second, 
independent cohort comprising 12 controls and 13 AD patients (replication cohort). 
To investigate the potential usage as novel biomarkers, we additionally partially 
validated and replicated top-ranking hits in DNA derived from whole blood.   
In BPD, various genes have been found to be differentially methylated. However, 
their value as predictive epigenetic biomarker has not been assessed so far. Here, 
we aimed to verify previous results and investigate the predictive role of DNA 
methylation levels of APBA3, MCF2 and NINJ2 on therapy outcome in BPD patients. 
Therefore, we compared 44 BPD patients to 44 controls, who were matched for sex 
and age. To identify treatment-associated alterations in DNA methylation and the use 
as novel predictive epigenetic biomarker, we compared patients responding to DBT 
to non-responders pre- and posttreatment. 
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3 Results and Discussion 
3.1 Study cohorts 
3.1.1 Alcohol dependence cohorts 
Three cohorts have been used in this work. The EWAS analysis was conducted in 
the discovery cohort (Table 2) and the EWAS results were validated in the replication 
cohort (Table 3). Replication of GDAP1 DNA methylation took place in parts of the 
above-mentioned cohorts as well as additionally recruited individuals (Table 4). We 
thereby emphasized on matching as closely as possible for the following aspects: 
First, we only included male participants in our study. Second, all participants were 
Caucasian, with all subjects from German descent except one Polish and one 
Russian participant. Third, since smoking has a vast impact on DNA methylation as 
mentioned before, we matched the percentage of smokers in each cohort, and within 
the smokers, we matched the amount of consumed nicotine as closely as possible. 
Table 2: Description of the discovery alcohol dependence cohort. 
Amount of drinks consumed daily derived from the AUDIT-questionnaire. P-values were computed 
using independent samples t-tests. Errors are given as standard deviation (SD). 
 Patients Controls P-value 
N 24 23  
Age (years) 47.5 ± 10.1 46.9 ± 10.3 0.8 
Smokers (% of total) 19 (79%) 18 (78%) 0.9 
Cigarettes smoked daily 15.2 ± 10.7 13.8 ± 12.6 0.7 
AUDIT-score 24 ± 6.5 5.9 ± 3.8 4E-15 
Days since last drink 1.2 ± 0.6   
Amount of drinks consumed daily in  
  the week before hospital admission 
13.7 ± 8.3 
  
Years of alcohol dependence 10.6 ± 9.4   
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Table 3: Description of the replication alcohol dependence cohort. 
Amount of drinks consumed daily derived from the AUDIT-questionnaire. P-values were computed 
using independent samples t-tests. Errors are given as standard deviation (SD). 
 Patients Controls P-value 
N 13 12  
Age (years) 50.9 ± 9.1 45.3 ± 16.2 0.4 
Smokers (% of total) 9 (69%) 8 (67%) 0.9 
Cigarettes smoked daily 10.5 ± 9.4 8.9 ± 8.0 0.7 
AUDIT-score 28.0 ± 4.9 2.8 ± 2.3 3E-14 
Days since last drink 0.3 ± 0.4   
Amount of drinks consumed daily in  
  the week before hospital admission 
19 ± 11.4 
  
Years of alcohol dependence 14.6 ± 11.7   
 
Table 4: Description of the GDAP1 alcohol dependence cohort. 
Amount of drinks consumed daily derived from the AUDIT-questionnaire. P-values were computed 
using independent samples t-tests. Errors are given as standard deviation (SD). 
 Patients Controls P-value 
N 49 37  
Age (years) 49 ± 10.47 47 ± 12.32 0.3 
Smokers (% of total) 38 (79%) 29 (78%) 0.9 
Cigarettes smoked daily 20 ± 10.93 16 ± 10.99 0.2 
AUDIT-score 25.1 ± 6.1 4.9 ± 3.7 5E-15 
Days since last drink 2.9 ± 6.9   
Amount of drinks consumed daily in  
  the week before hospital admission 
17 ± 13.1 
  
Years of alcohol dependence 12.3 ± 9.9   
 
3.1.2 Psychological effects of the alcohol treatment program 
In order to quickly assess the impact of the alcohol treatment program on the 
psychological wellbeing, patients answered the SCL-90-R questionnaire pre- and 
posttreatment, reflecting changes in their global distress level (GSI score). 
Additionally, to investigate the influence of the alcohol treatment program on alcohol 
craving, we assessed the OCDS score. The OCDS score was calculated as 
previously described [118]. In the GDAP1 cohort, calculation was adjusted by dividing 
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the score by the number of answered items, to allow up to two unanswered items 
without having an effect on the final score (Table 5 b). 
Table 5: Pre- and posttreatment comparison of the discovery and GDAP1 cohorts. 
P-values were computed using paired-samples t-tests. Errors are given as standard deviation (SD).  
* OCDS score was divided by the number of answered items. 
 Patients (T1) Patients (T2) P-value 
a) Discovery cohort 
N 24 24  
GSI score 0.72 ± 0.45 0.41 ± 0.52 0.036 
OCDS score 19.3 ± 6.6 12.0 ± 4.9 3E-05 
 
b) GDAP1 cohort 
N 49 33  
GSI score 0.78 ± 0.54 0.48 ± 0.49 0.008 
OCDS score* 3.93 ± 1.32 2.71 ± 0.96 2E-05 
 
We found that the alcohol treatment program significantly reduced the global distress 
level of the patients as well as the craving for alcohol (Table 5), indicating that the 
alcohol treatment has a positive impact on the general well-being of the patients. To 
date, psychological questionnaires are the means of choice when evaluating 
treatment outcome. However, this measure is biased by the subjective well-being of 
the individual subjects and does not reflect an objective measure. Finding a 
biomarker measuring surrogate endpoints would circumvent this limitation and is a 
major field of current research. 
 
3.1.3 BPD cohort 
The BPD cohort consisted of 44 BPD patients and 44 age- and sex-matched healthy 
controls (Table 6). This BPD study cohort has been reported as part of a previous 
thesis [119]. 
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Table 6: Description of the BPD cohort. 
P-values were computed using independent samples t-tests. Errors are given as standard deviation 
(SD). 
 Patients Controls P-value 
N (male / female) 44 (7 / 37) 44 (7 / 37)  
Age (years) 29.5 ± 8.4 29.7 ± 8.8  
GSI t-score 79.00 44.73 2E-16 
BSL23 score 2.42 0.22 5E-15 
 
3.2 Epigenetic dysregulation in alcohol dependence 
We performed an EWAS analysis on Illumina’s 450K beadchip array. Raw values 
acquired by Illumina’s GenomeStudio were subject to preprocessing and cell type 
deconvolution, as described in the following paragraph. 
 
3.2.1 Preprocessing 
Preprocessing of probes is an essential step to improve the quality of the acquired 
data. We therefore removed single-nucleotide polymorphism (SNP) probes, probes 
with missing beta value or bad detection P-value and polymorphic (cross-hybridizing) 
probes (Table 7). 
Table 7: Preprocessing of the 450K raw data. 
Preprocessing step Probes Probe number left 
Initial probes  485,577 
SNP probes 65 485,512 
Missing beta value / bad detection P-value 13,903 471,609 
Polymorphic probes 19,343 452,266 
Final dataset  452,266 
 
After this initial processing, the data was normalized using the Subset-quantile Within 
Array Normalization (SWAN [120]), normalizing the technical differences between 
probe types on the 450K beadchip array and ComBat [121], removing batch effects 
such as chip and position-on-chip effects. 
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A key rationale of our study was to restrict our DNA methylation analysis to T cells, 
which are directly influenced by AD, to eliminate cell type heterogeneity and avoiding 
post-analytical bioinformatic removal of it. Although we purified T cells from our 
samples with affinity binding of the CD3 receptor via magnetic beads, we additionally 
checked for residual cell contamination using a bioinformatics approach described in 
a previous publication [122]. The analysis showed contamination of the purified T cell 
samples especially with natural killer (NK) cells. We aimed to verify these results 
experimentally by conducting a fluorescence-activated cell sorting (FACS) analysis. 
Because the magnetic beads used to purify T cells interfered with the fluorescence 
measurements, we detached the cells from the beads which led to a decrease in their 
viability. Further, only 15% of the bead-detached cells showed a positive signal for 
CD3, if analyzed immediately. However, when incubating the cells for 16 hours after 
detachment, 90% showed a positive CD3 signal. Additional analysis of the cells by 
size and granularity confirmed that 92% of the viable cells were T cells. Presumably, 
the initially measured low CD3 signal was a result of CD3 receptor internalization 
after binding to the magnetic beads, while the receptor was recycled back to the cell 
surface after 16 hours of incubation [123]. 
Since these results were in accordance with the bioinformatic analysis, which 
predicted an average non-T cell contamination of 5%, we bioinformatically removed 
contaminating cell types resulting in the final dataset that was used for further 
analysis. The very low discrepancy of less than 5% between the bioinformatics 
results and the experimental FACS results makes the data plausible and the residual 
discrepancy could potentially have been eliminated if viability of the cells after 16 
hours had been improved, thus measuring a greater number of cells. 
 
3.2.2 Global DNA methylation 
To assess the genome-wide influence of AD on DNA methylation, we calculated 
global DNA methylation as the average of DNA methylation values across all 
interrogated sites in each sample. We found that patients had a lower mean global 
DNA methylation before treatment as compared to controls. However, after the 
treatment, global DNA methylation values were higher and did not differ significantly 
from controls any more (Figure 3). 
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Figure 3: Global DNA methylation levels. 
Patients pre-treatment (T1) show significantly lower global DNA methylation compared to controls  
(P = 0.048, Mann-Whitney U test). After the treatment (T2), mean DNA methylation did not differ from 
the controls any more. 
 
The fact that AD can lead to global DNA methylation changes has been shown 
previously, however, the results were conflicting. While some studies showed a 
global hypermethylation [124, 125] others found global hypomethylation [96, 99, 100, 
113]. Additionally, the reversal of DNA methylation to control-like levels after 
treatment was also found by Philibert et al. [112].  
Initially, global hypermethylation in AD patients was explained by the elevation of 
homocysteine as a result of alcohol consumption. It was hypothesized that through 
the higher levels of homocysteine, which is hydrolyzed to methionine and in a further 
step converted to SAM, more methyl group donors would form and subsequently 
would stimulate DNA methylation [125]. However, a more recent, extensive study 
could not find an association between elevated homocysteine levels and global DNA 
methylation [98]. Contrarily, another hypothesis states that due to alcohol 
consumption, regulation of methionine adenosyl transferase is impaired and, 
therefore, global DNA methylation levels decrease [99, 100]. In summary, little is 
known about the exact relationship between altered homocysteine levels and DNA 
methylation and, up to now, results often are contradictory [126]. Since we did not 
measure homocysteine levels or methionine adenosyl transferase activity, we can 
neither support nor refute a certain theory. 
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3.2.3 Site-specific analysis results 
Two parameters can be adjusted in analyses of high-throughput experiments such as 
an EWAS. First, P-Values have to be adjusted for multiple testing. We adjusted our 
dataset applying the Benjamini-Hochberg false discovery rate (FDR) method [127]. 
However, considering the small sample size, we adjusted the significance level to 
FDR < 0.1, as done in several other studies [128, 129]. With a more stringent FDR, 
relevant sites could potentially be dismissed in a very early step of the analysis. 
Second, to compensate for the higher FDR value, we aimed to increase the likelihood 
of finding biological relevant hits. Therefore, we only analyzed hits with a DNA 
methylation difference (Δ-beta) of more than 5% between groups. Table 8 displays 
the number of hits for different thresholds of these two parameters in our dataset. 
Table 8: Number of significant hits at different FDR and Δ-beta thresholds. 
 FDR < 0.2 FDR < 0.1 FDR < 0.05 
Δ-beta > 0 17,342 1210 47 
Δ-beta > 0.05 305 59 5 
Δ-beta > 0.1 17 4 0 
 
First, we compared DNA methylation between controls and patients before treatment, 
and found 59 CpG sites to be differentially methylated (Table S 1). 
Second, to investigate the effect of the alcohol treatment program, we compared 
DNA methylation between patients pre- and post-treatment and found 48 CpG sites 
differentially methylated, which were all less methylated before treatment (Table S 2). 
Our top-ranked hit HECW2 from the comparison of controls and patients encodes a 
HECT-type E3 ubiquitin ligase which is involved in the cellular stress response [130, 
131]. This finding is in line with previous evidence for the role of epigenetic regulation 
of cellular stress response genes in AD, such as GDAP1, which was identified in a 
previous EWAS [112] and replicated in whole blood samples as part of this thesis. 
Another top hit, SRPK3, encodes a serine/arginine protein kinase and plays an 
important role in the development of the skeletal muscle [132]. However, its homolog 
SRPK79D in Drosophila melanogaster plays an important role in the function of 
synapses [133]. The high amino acid homology between SRPK79D and SRPK3 of 
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65% might indicate a role of SRPK3 in the nervous system, which has not yet been 
determined. 
Further hits from our analysis have been associated with AD. For example, LIPA, the 
Lysosomal Acid Lipase A, has been shown to have a lower activity in non-alcoholic 
fatty liver disease [134]. In addition, TNFSF10 and SKIL are associated with different 
types of cancer, which is a common comorbidity in AD patients. TNFSF10 is 
associated with hepatocellular carcinomas [135] and SKIL can act as tumor 
suppressor [136]. Since the fourth-ranked hit, cg07280807, is in an intergenic area, 
and the nearest gene (SMOC1) is approximately 30,000 base pairs upstream, we 
additionally performed a motif analysis with JASPAR [137] for this site. The motif 
analysis revealed putative binding sites for JunB, Fos, FosL1 and Fos:Jun. Fos and 
Jun can form the activator protein 1 (AP-1) complex, which has been linked to 
ethanol intake and withdrawal in animal models [138, 139]. Many other hits in the 
site-specific analysis are sites and genes, which have not been associated with AD 
before. In addition, we did not find overlapping hits to previous EWAS. However, 
since these studies have used different cell types for their analyses, different cohorts 
and different study designs, this was not surprising. Furthermore, for these reasons, 
EWAS published to date do not show substantial overlapping hits.  
It is not surprising that top hits are within the biological processes of cellular stress 
response (i.e. HECW2) or generally related to cancer (i.e. TNFSF10, SKIL), since 
both fields play a major role in AD. First, a recent meta-analysis showed that AD can 
cause cancer at not less than seven sites in the body [140]. Second, cellular stress 
response is essential to counteract ethanol intake and its toxic effects. In the study by 
Liu et al., stress response was also one of the top enriched processes [113]. 
However, gene ontology enrichment analysis of our own study did not show 
significantly enriched pathways, which is most likely caused by the low number of 
significant hits. 
 
3.2.4 Regional analysis results 
Although it was shown that single CpG sites in promoter regions can impact gene 
expression, DMRs can control cell-type-specific transcriptional repression of an 
associated gene more effectively [141]. To identify entire regions spanning several 
single CpG sites which are differentially methylated, we performed DMRcate 
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analyses and found 29 DMRs between controls and patients pre-treatment (Table S 
3). Interestingly, SRPK3 was found differentially methylated in both the site-specific 
and regional analysis, indicating that SRPK3 is a robust hit in our analyses. Between 
patients pre- and post-treatment, we did not identify significant DMRs. Presumably, 
three weeks of treatment were not sufficient to significantly alter the methylation of an 
entire region. 
 
3.2.5 Post-treatment reversion of differential DNA methylation 
Global DNA methylation analysis already showed that mean methylation levels 
across all sites no longer differed from the controls’ levels after alcohol treatment 
(Figure 3). This was confirmed by the majority of the hits from the site-specific 
analysis: 7 out of 59 sites showed a complete reversion of DNA methylation to 
controls’ levels. Another 32 sites showed a trend to revert back, although not 
statistically significant. The DNA methylation of only 20 sites did not change from pre- 
to posttreatment. This phenomenon of reverting DNA methylation following treatment 
has been observed previously in the study of Philibert and colleagues. They found 
that 49 out of 56 significant sites showed reversal of DNA methylation after short-
term alcohol treatment [112]. Additionally, other studies showed similar effects after a 
particular treatment, such as after one month of anti-TNF-α treatment in psoriatic 
patients [142] or in-vitro treatment of different cancer cell lines with polyphenols [143]. 
The reversal of DNA methylation and the accompanying change in gene expression 
could be one key mediator of recovery. 
 
3.2.6 Validation 
As reviewed by Mill et al. [144], high-throughput experiments such as the 450K 
beadchip array are prone to false-positive (type I error) results and, therefore, ought 
to be validated. As described earlier, decreasing costs of high-throughput assays led 
to massive replication studies of GWAS experiments, often not being able to validate 
initial candidate-gene driven study findings. In general, validation should be carried 
out using a different methodology to avoid errors specific to a certain technique. 
Therefore, we validated our top-ranked hits cg18752527 (HECW2), cg07280807 
(intergenic), cg16529483 and cg24496423 (both SRPK3) by pyrosequencing in the 
discovery cohort. We found all four sites to be differentially methylated between 
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patients and controls with a high correlation between the measurements of the 
different methodologies (Table 9). 
 
3.2.7 Replication 
Although we already took several precautions to avoid false positive findings in our 
EWAS analyses as described before, we additionally replicated our four top-ranked 
hits, which we successfully validated in the discovery cohort. Therefore, we assessed 
methylation levels for these sites by pyrosequencing in an independent cohort 
comprised of 13 AD patients and 12 controls. We found that the intergenic CpG site 
cg07280807 and cg18752527 (HECW2) were also differentially methylated in this 
cohort (one-sided t-test, FDR < 0.05, Table 9).  
However, although cg16529483 and cg24496423 in the SRPK3 gene were higher 
methylated in patients of our replication cohort, the differences were not significant 
(Table 9). Although the differences in DNA methylation observed in the replication 
cohort still had the same direction of change, the extent of methylation differences 
varied: cg24496423 in the SRPK3 gene, which had the second biggest difference in 
the discovery cohort, did not replicate, whereas HECW2, whose DNA methylation 
difference was smaller in the discovery cohort, did. Presumably, the replication cohort 
with only 25 subjects was too small to achieve statistically robust results. 
Table 9: Overview of validation and replication results. 
Successful validation or replication is marked with a (+), whereas sites failing to validate or replicate 
are marked with a (–). * FDR-corrected P-Values between patients and controls; Validation, Welch’s t-
test; Replication, one-sided t-test. 
Site (gene) Validation (P-Value*) Replication (P-Value*) 
cg07280807 (intergenic) + (1.5E-03) + (0.048) 
cg18752527 (HECW2) + (2.7E-06) + (0.048) 
cg16529483 (SRPK3) + (1.2E-03) – (0.183) 
cg18752527 (SRPK3) + (1.6E-03) – (0.298) 
 
3.2.8 Whole-blood replication 
Since one aim of this work was to identify differentially methylated sites that could 
potentially be used as biomarkers in clinical settings, we aimed to replicate the 
above-mentioned top-ranked hits in DNA derived from whole blood. In order to serve 
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as a biomarker, the study material should be easy and cost effective to obtain. This is 
not applicable for purified T cells, as the purification process is time consuming and 
cost intensive. Furthermore, T cells can only be purified from freshly drawn blood 
since freezing the specimen would damage the cells and cause cell death leading to 
the inability to recover a particular cell type. Finding differentially methylated sites in 
DNA derived from whole blood would therefore be extremely useful, since immediate 
processing is not necessary and purification of T cells could be omitted.  
We found significant correlations between DNA methylation levels of cg07280807 
from T cells and whole blood, both measured by pyrosequencing in the discovery and 
replication cohort, but we could not replicate the differential methylation between the 
patient and control group in whole blood. However, as in the EWAS analysis, patients 
had higher methylation values at this site, though not statistically significant. 
Potentially, differential DNA methylation of cg07280807 is unique to T cells, and not 
shared by other blood cells. 
Still, we were able to show differential HECW2 and SRPK3 DNA methylation in whole 
blood, implicating their use as potential novel biomarkers for AD. However, since this 
is the first study to find these two genes associated with AD, other studies have to 
verify these results. Because biomarkers should be easily and widely applicable, 
future studies should also investigate HECW2 and SRPK3 DNA methylation in 
different ethnic groups, since we restricted our analyses to Caucasian subjects. 
 
3.2.9 Replication of differential GDAP1 DNA methylation 
GDAP1 was one top-ranked differentially methylated gene in the study by Philibert 
and colleagues [112]. However, they neither validated nor replicated their findings. 
Since the study design showed some similarity to ours, i.e. investigating AD and the 
effects of short-term alcohol treatment, we sought to reproduce this finding in whole 
blood DNA of our GDAP1 alcohol dependence cohort, which was comprised of 49 
patients and 37 controls. We found that 3 closely spaced CpG sites in the GDAP1 
gene promoter region, including cg23779890, previously reported by Philibert et al., 
were lower methylated in patients compared to controls. Similarly to the findings of 
Philibert and to our EWAS analyses, we again found that the DNA methylation 
differences were reversible by the alcohol treatment: After three weeks of attending 
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the alcohol treatment program, DNA methylation reverted back to a level where it no 
longer differed significantly from controls. 
However, GDAP1 did not appear as one of the top hits in our previously described 
EWAS analysis using DNA isolated from purified T cells. Presumably, the differential 
methylation of GDAP1 in whole blood is driven by another cell type than T cells, 
which could explain why Philibert and colleagues found GDAP1 differentially 
methylated in PBMCs and we found it in whole blood, but not in T cells. 
 
3.2.10   SRPK3 and GDAP1 gene expression in whole blood 
To elucidate the effect of differential SRPK3 and GDAP1 DNA methylation on the 
gene expression of the respective genes, we performed qPCR of whole blood mRNA 
samples from the cohort used for analyzing GDAP1 [145]. While the gene expression 
levels of GDAP1 did not differ, SRPK3 showed lowered gene expression in patients 
pre-treatment by one fourth compared to controls, though the effect was not 
statistically significant (relative quantification: controls = 1, patients (T1) = 0.75, P = 
0.3, Figure 4). Post-treatment, gene expression levels were elevated again and were 
similar to those of controls (relative quantification: controls = 1, patients (T2) = 1.11, 
P = 0.8, Figure 4). 
 
Figure 4: Gene expression of SRPK3. 
In comparison to controls, whose expression levels were set to 1, expression levels of patients (T1) 
were 0.75 (P = 0.3) and patients (T2) were 1.11 (P = 0.8). Error bars depict min-max values. From 
Gräf Olmos, V. Bachelor thesis, 2017 [145]. 
 
GDAP1 DNA methylation was already very low, ranging from 2 to 8%, and the 
difference between controls and patients was only 1.2%. Therefore, it was not 
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surprising that we could not detect an altered gene expression. The findings relating 
SRPK3 are in accordance to the methylation data, as we expected lower gene 
expression due to the higher methylation levels in patients pre-treatment compared to 
healthy controls. Apart from the small effect size, the overall very low expression of 
SRPK3 we found in whole blood could explain that the results were not statistically 
significant. However, our finding is consistent with the data from the Expression Atlas 
by the European Molecular Biology Laboratory [146], where SRPK3 expression in 
whole blood was below cut-off measured with an Affymetrix microarray [147]. 
 
3.2.11   Conclusion & Outlook 
In conclusion, we showed differential methylation of various genes associated with 
AD in disease-relevant T cells. In addition, we found a unique set of genes 
differentially methylated in patients pre- and posttreatment, implicating their potential 
role in alcohol abstinence and early recovery. Furthermore, we showed that alcohol 
dependent patients exhibit global DNA hypomethylation which reverts back after 3 
weeks of attending an alcohol treatment program. This data could contribute to the 
identification of genes playing an important role in AD. To strengthen the results 
acquired with Illumina’s 450K beadchip array, we validated our top-ranked hits and 
replicated them in an independent cohort.  
Our finding of differential methylation of HECW2 and SRPK3 in whole blood DNA 
indicates their potential value as novel blood-based biomarkers for AD. By showing 
differential SRPK3 DNA methylation and altered gene expression levels as shown by 
lower SRPK3 mRNA levels (although not statistically significant), we substantiate the 
potential use of SRPK3 as biomarker. 
However, the explanatory power of our study is limited by the following factors: First, 
the cohort size was limited and should be increased in subsequent studies. Second, 
despite all the advantages, the 450K beadchip array itself has some limitations. 
Some of them, such as cross-hybridization of certain probes, SNPs within probes and 
technical variation (batch effects), have been mostly solved using bioinformatic 
approaches. In addition, the array only covers around 2% of CpG sites in the entire 
genome [148] and has a great bias for CpG sites within promoter regions, thereby 
missing potentially important sites, which are not interrogated. At the time of creation, 
this seemed meaningful, since promoter CpG sites were well studied and their impact 
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on gene expression was shown in several studies. However, more recent work 
supports the importance of non-promoter CpG methylation such as in enhancer 
regions. For this reason, a newer beadchip array (850K, EPIC) was recently 
developed, adding over 330,000 sites in these regions [149]. Third, we cannot 
generally rule out that the effects we observed between pre- and posttreatment 
derived from stochastic temporal variation rather than from alcohol treatment. 
However, accounting for this in a controlled way is nearly impossible, since controls 
would have to adjust their entire lifestyle, including physical activity and nutrition, 
according to the matched patient. In addition, previous studies showed no big 
influence of temporal variation on the methylation levels interrogated by the 450K 
beadchip array [150]. 
Since AD is an addiction, it is meaningful to study effects of AD in brain tissue. 
However, it is not possible to gain this tissue from living study subjects. The most 
commonly used approach is to study whole blood DNA methylation as easily 
obtainable surrogate measure. However, as discussed earlier, methylation profiles 
between whole blood and brain tissue can vary substantially. Another approach is to 
indeed use brain tissue of post-mortem samples. Here, study material is drastically 
limited and, therefore, matching sufficiently sized cohorts is considerably impeded. 
Since this is the first study to assess differential methylation levels in T cells from AD 
patient and we present unique and novel sets of differentially methylated sites and 
regions, further studies are needed to additionally validate our results. The primary 
focus should be on the evaluation of HECW2 and SRPK3 DNA methylation, since 
these are the most promising candidates for a novel biomarker. However, future 
functional studies should also elucidate possible mechanisms of how these genes 
contribute to the onset or recovery of AD. First implications have been discussed in 
this work and should be followed up. 
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3.3 Epigenetic dysregulation in BPD 
3.3.1 Comparison of controls and patients 
Due to the small number of studies concerning BPD and epigenetics so far, more 
work is needed to elucidate potential associations. We therefore analyzed 
methylation levels of APBA3 and MCF2 by pyrosequencing in the BPD cohort 
comprised of 44 patients and 44 controls, seeking to validate and replicate the 
findings of previous work [31] and, more importantly, to investigate the effect of DBT 
treatment on DNA methylation. Neither APBA3, nor MCF2 were differentially 
methylated between controls and patients. To investigate if DBT had an effect on 
DNA methylation, we additionally compared 24 patients before and after DBT 
intervention. However, we did not find significant differences in this comparison 
either. Since we were not able to obtain a PCR product of sufficient quality for further 
analysis, methylation analysis of the NINJ2 gene was not possible.  
 
3.3.2 Comparison of responders and non-responders 
Although DBT intervention has been investigated in several non-epigenetic studies, a 
predictive biomarker for treatment outcome does not exist to date. To investigate the 
predictive power of DNA methylation for treatment success, we divided the patients 
concluding treatment in responders and non-responders. Usually, this classification is 
based on the reduction of self-harming tendencies, which is the primary intent of DBT 
[151]. Unfortunately, we did not retrieve this data for our BPD patient cohort. 
Therefore, we chose two psychological questionnaires as surrogate measures for 
response or non-response to DBT: Patients were classified as responders if the GSI 
t-score calculated from the SCL-90-R questionnaire, which reflects psychological 
well-being, was lowered by at least 5 points. This reflects a moderate decline of the 
overall psychological burden. In addition, only if the BSL-23 score, measuring BPD 
symptoms, was below 2.05 after therapy patients were classified as responders. This 
score was chosen as it was the average score achieved by patients in earlier studies 
[152]. However, the mean BSL-23 score in our cohort was considerably higher (2.42), 
which is why we chose to apply a score of 2.05 as cut-off value. This classification 
led to a total of 7 responders and 17 non-responders. 
Comparing responders and non-responders, we found significant differences in both 
APBA3 and MCF2 DNA methylation. Both genes were hypermethylated in 
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responders, with mean methylation levels being 13% higher than in non-responders 
for MCF2. In addition, we found an inverse correlation between BPD severity and 
DNA methylation: Higher DNA methylation pre-treatment resulted in lower GSI t-
scores after the treatment. Interestingly, after treatment, methylation values of 
responders and non-responders did not differ significantly any longer.  
To date, except the previous study by Teschler et al. [31], neither APBA3 nor MCF2 
have been associated with BPD. However, associations with other psychiatric 
disorders such as Alzheimers’ disease (APBA3 [153]), schizophrenia and autism-
spectrum disorders (MCF2 [154]) have been described previously, suggesting a 
possible, but not yet discovered role of these genes in BPD. 
 
3.3.3 Conclusion & Outlook 
Here, we aimed to replicate the differential DNA methylation of APBA3 and MCF2 in 
BPD patients, but found no significant differences compared to controls. Additionally, 
we did not detect any significant influence of DBT on the DNA methylation of those 
genes by comparing the patients pre- and post-treatment. These results do not 
support the findings of the study by Teschler et al., who showed aberrant DNA 
methylation of both APBA3 and MCF2 between their BPD and control cohorts [31]. 
However, we found APBA3 and MCF2 to be significantly hypermethylated at the 
beginning of treatment in patients responding to DBT compared to non-responders. 
This supports the hypothesis that DNA methylation of APBA3 and MCF2 could serve 
as an epigenetic biomarker with predictive value for DBT therapy outcome in BPD 
patients.  
Compared to the previous study [31], we were able to almost double the number of 
patients and quadruple the number of controls, gaining higher statistical power and, 
therefore, an important reduction in the possibility of false-positive findings. Still, 
especially considering the size of the responder/non-responder cohort, one main aim 
should be to increase its size in future studies. Additionally, to facilitate and 
standardize classification, self-harming behavior should be monitored in upcoming 
studies, since this is the reference measure of response to DBT. 
Although associations with other psychiatric diseases have been shown for both 
genes, the link to BPD is unknown to date. Subsequent studies have to be conducted 
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to clearly decipher the role of both ABPA3 and MCF2 in BPD. Furthermore, their 
function as predictive biomarkers for BPD should be validated in a larger cohort.  
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6 Supplement 
6.1 Tables 
 
Table S 1: Site-specific analysis results between controls and patient (T1). 
Hits are sorted by FDR-Value. 
 Probe ID Gene Region P-Value FDR Δ-beta Average 
beta 
controls 
Average 
beta 
patients (T1) 
1 cg18752527 HECW2 intragenic 4.30E-07 0.021 0.066 0.342 0.276 
2 cg08109624 None intergenic 8.15E-07 0.023 -0.057 0.760 0.817 
3 cg10168086 None intergenic 1.24E-06 0.026 0.051 0.535 0.484 
4 cg07280807 None intergenic 2.44E-06 0.037 -0.068 0.755 0.822 
5 cg12173150 None intergenic 3.02E-06 0.037 -0.064 0.321 0.385 
6 cg01059398 TNFSF10 intragenic 1.07E-05 0.063 0.052 0.261 0.209 
7 cg17940902 HLA-DMA promoter 1.19E-05 0.064 -0.051 0.399 0.450 
8 cg22778903 MX2 intragenic 1.34E-05 0.067 -0.051 0.304 0.355 
9 cg14612335 SKIL promoter 1.38E-05 0.067 0.055 0.423 0.368 
10 cg11580026 None intergenic 1.51E-05 0.069 0.051 0.600 0.549 
11 cg12284098 MYOM2 intragenic 1.54E-05 0.069 0.056 0.534 0.477 
12 cg26091609 CTLA4 intragenic 1.59E-05 0.069 0.060 0.578 0.518 
13 cg09768654 SRPK3 promoter 1.65E-05 0.069 -0.092 0.374 0.466 
14 cg06851207 PNMAL1 promoter 1.84E-05 0.069 -0.089 0.528 0.617 
15 cg14702960 None intergenic 1.92E-05 0.069 0.052 0.742 0.689 
16 cg00449728 MAPRE2 intragenic 2.98E-05 0.070 0.057 0.750 0.693 
17 cg22851561 ELMSAN1 intragenic 3.00E-05 0.070 0.052 0.432 0.380 
18 cg02536838 ANGPT1 promoter 3.14E-05 0.070 0.075 0.605 0.530 
19 cg15841511 None intergenic 3.42E-05 0.071 -0.059 0.729 0.788 
20 cg24392939 CRYBG3 intragenic 3.62E-05 0.072 0.052 0.562 0.510 
21 cg12761472 CEP85L promoter 4.13E-05 0.075 0.055 0.621 0.566 
22 cg02652579 SYNGAP1 promoter 4.17E-05 0.076 0.059 0.623 0.563 
23 cg22865905 SNORA69 three_plus 4.26E-05 0.076 0.051 0.794 0.743 
24 cg27201673 PNMAL1 promoter 5.41E-05 0.078 -0.050 0.213 0.263 
25 cg04936619 C17orf75 intragenic 5.88E-05 0.078 0.069 0.314 0.245 
26 cg11121969 PCBP3 promoter 6.26E-05 0.078 0.064 0.691 0.627 
27 cg00246693 ARHGAP42 promoter 7.10E-05 0.078 -0.053 0.340 0.393 
28 cg10399005 None intergenic 7.11E-05 0.078 -0.057 0.776 0.833 
29 cg16529483 SRPK3 promoter 7.18E-05 0.078 -0.105 0.252 0.357 
30 cg01220513 SH3KBP1 intragenic 8.08E-05 0.079 0.051 0.506 0.454 
31 cg26926002 None intergenic 8.10E-05 0.079 -0.058 0.719 0.777 
32 cg14544087 MIR155HG intragenic 8.64E-05 0.079 0.063 0.290 0.227 
33 cg20893919 TRPC3 intragenic 9.23E-05 0.080 -0.051 0.703 0.754 
34 cg18682028 FYCO1 intragenic 9.24E-05 0.080 0.056 0.394 0.338 
35 cg04362790 None intergenic 9.32E-05 0.080 0.052 0.697 0.644 
36 cg09060654 LIPA intragenic 9.51E-05 0.080 -0.079 0.578 0.656 
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 Probe ID Gene Region P-Value FDR Δ-beta Average 
beta 
controls 
Average 
beta 
patients (T1) 
37 cg02451774 NBPF8 intragenic 9.98E-05 0.081 -0.053 0.431 0.483 
38 cg18723276 USP29 promoter 1.10E-04 0.082 -0.051 0.723 0.774 
39 cg13180722 None intergenic 1.19E-04 0.083 -0.062 0.338 0.401 
40 cg12230162 SRPK3 promoter 1.20E-04 0.083 -0.105 0.357 0.463 
41 cg18890544 None intergenic 1.23E-04 0.084 -0.059 0.846 0.905 
42 cg24496423 SRPK3 promoter 1.30E-04 0.085 -0.084 0.309 0.393 
43 cg02661764 None intergenic 1.35E-04 0.087 0.059 0.419 0.360 
44 cg01400671 None intergenic 1.40E-04 0.087 0.064 0.409 0.345 
45 cg13609457 None intergenic 1.52E-04 0.090 0.056 0.577 0.521 
46 cg25880958 None intergenic 1.52E-04 0.090 -0.054 0.591 0.645 
47 cg18376497 INPP4B intragenic 1.65E-04 0.092 0.064 0.286 0.223 
48 cg13784312 RAPGEF1 intragenic 1.72E-04 0.093 0.051 0.187 0.136 
49 cg07135405 MIR1914 three_plus 1.76E-04 0.093 0.146 0.540 0.394 
50 cg20475486 None intergenic 1.80E-04 0.094 -0.058 0.702 0.759 
51 cg11858450 CCDC105 intragenic 1.89E-04 0.094 -0.053 0.709 0.762 
52 cg05927817 None intergenic 1.94E-04 0.094 -0.061 0.726 0.787 
53 cg00306893 None intergenic 1.99E-04 0.094 0.062 0.737 0.675 
54 cg10365886 TNXB intragenic 2.08E-04 0.095 -0.105 0.566 0.672 
55 cg27503950 None intergenic 2.19E-04 0.095 -0.063 0.633 0.696 
56 cg01089001 GALNT18 intragenic 2.27E-04 0.095 -0.065 0.317 0.382 
57 cg12564698 GAL three_plus 2.30E-04 0.095 0.051 0.312 0.261 
58 cg16197188 NRG3 intragenic 2.59E-04 0.100 0.051 0.723 0.672 
59 cg04088338 None intergenic 2.66E-04 0.100 0.052 0.430 0.378 
 
 
Table S 2: Site-specific analysis results between patients pre- and posttreatment. 
Hits are sorted by FDR-Value. 
 Probe ID Gene Region P-Value FDR Δ-beta Average 
beta 
patients 
(T1) 
Average 
beta 
patients 
(T2) 
1 cg15500907 LAMA4 intragenic 1.01E-06 0.032 -0.056 0.485 0.542 
2 cg05266321 CCR2 intragenic 4.63E-06 0.049 -0.061 0.545 0.606 
3 cg13279700 C6orf10 intragenic 1.76E-05 0.056 -0.063 0.481 0.544 
4 cg14054990 KRTAP19-5 promoter 1.84E-05 0.056 -0.052 0.431 0.482 
5 cg21049302 None intergenic 1.98E-05 0.056 -0.056 0.466 0.522 
6 cg17022548 NRG2 intragenic 1.99E-05 0.056 -0.054 0.204 0.258 
7 cg22472360 TRIO intragenic 2.09E-05 0.057 -0.055 0.514 0.569 
8 cg07920414 RIMS3 intragenic 2.18E-05 0.057 -0.055 0.438 0.493 
9 cg04088338 None intergenic 2.54E-05 0.059 -0.051 0.378 0.429 
10 cg12240358 HOMER2 intragenic 2.68E-05 0.059 -0.057 0.462 0.519 
11 cg09712306 AURKA intragenic 3.48E-05 0.060 -0.058 0.602 0.660 
12 cg07939743 None intergenic 3.50E-05 0.060 -0.052 0.289 0.341 
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 Probe ID Gene Region P-Value FDR Δ-beta Average 
beta 
patients 
(T1) 
Average 
beta 
patients 
(T2) 
13 cg00803692 CCR5 promoter 3.73E-05 0.062 -0.054 0.370 0.424 
14 cg10177030 SNORD12 three_plus 3.85E-05 0.063 -0.053 0.419 0.472 
15 cg15439110 None intergenic 3.93E-05 0.063 -0.080 0.444 0.525 
16 cg20385229 SLIRP intragenic 4.13E-05 0.063 -0.052 0.392 0.444 
17 cg02393640 LUZP6 intragenic 5.63E-05 0.067 -0.052 0.390 0.443 
18 cg17863551 CD177 promoter 6.27E-05 0.067 -0.059 0.419 0.478 
19 cg15279541 None intergenic 7.14E-05 0.068 -0.051 0.388 0.439 
20 cg20171999 RRS1 three_plus 8.93E-05 0.068 -0.070 0.403 0.474 
21 cg20559385 None intergenic 9.43E-05 0.068 -0.052 0.428 0.479 
22 cg21429780 MAML3 intragenic 1.01E-04 0.068 -0.052 0.493 0.545 
23 cg01482790 HNRNPM intragenic 1.09E-04 0.068 -0.050 0.289 0.339 
24 cg20684197 FGF1 intragenic 1.10E-04 0.068 -0.051 0.395 0.445 
25 cg04279139 MANSC4 promoter 1.13E-04 0.069 -0.051 0.410 0.461 
26 cg16853860 PSMB9 intragenic 1.16E-04 0.070 -0.060 0.272 0.332 
27 cg27062514 CTR9 intragenic 1.33E-04 0.072 -0.064 0.463 0.526 
28 cg09931909 MB21D1 intragenic 1.40E-04 0.073 -0.077 0.420 0.497 
29 cg13340231 ZNF704 intragenic 1.50E-04 0.075 -0.055 0.528 0.583 
30 cg10035831 RPTOR intragenic 1.60E-04 0.075 -0.057 0.446 0.503 
31 cg13927756 MYO10 intragenic 1.62E-04 0.075 -0.056 0.468 0.524 
32 cg08749576 None intergenic 1.67E-04 0.076 -0.058 0.627 0.684 
33 cg15484808 RPS18 intragenic 2.20E-04 0.081 -0.054 0.480 0.534 
34 cg12802876 None intergenic 2.46E-04 0.083 -0.059 0.359 0.418 
35 cg03548415 None intergenic 2.93E-04 0.085 -0.051 0.422 0.473 
36 cg20547015 PPP1CC intragenic 3.02E-04 0.086 -0.064 0.453 0.517 
37 cg23214895 None intergenic 3.20E-04 0.088 -0.051 0.569 0.620 
38 cg12478092 CCDC116 promoter 3.28E-04 0.088 -0.063 0.510 0.573 
39 cg15683542 MIPEP intragenic 3.41E-04 0.088 -0.053 0.694 0.747 
40 cg09514545 MIR525 three_plus 4.04E-04 0.091 -0.060 0.442 0.501 
41 cg01789743 NID1 intragenic 4.11E-04 0.091 -0.053 0.499 0.552 
42 cg18524114 None intergenic 4.69E-04 0.093 -0.050 0.339 0.389 
43 cg04410448 ZC2HC1B intragenic 5.12E-04 0.095 -0.051 0.491 0.541 
44 cg13714407 RAPGEF1 intragenic 5.23E-04 0.095 -0.059 0.367 0.426 
45 cg27367066 None intergenic 5.63E-04 0.097 -0.054 0.455 0.510 
46 cg26837708 YBX1 intragenic 5.85E-04 0.097 -0.058 0.388 0.445 
47 cg14817867 PRPSAP2 intragenic 6.07E-04 0.097 -0.052 0.419 0.471 
48 cg13598358 PPP1CC intragenic 6.32E-04 0.098 -0.056 0.362 0.418 
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Table S 3: Regional analysis between controls and patients (T1). 
Hits are sorted by FDR-Value. 
 CGI coordinates Gene(s) No. of 
CpG sites 
FDR mean Δ-beta 
within region 
1 chrX:153046175-153047707 SRPK3 10 3.80E-19 -0.059 
2 chr1:242220301-242220925 None 5 1.02E-15 -0.054 
3 chr6:29648161-29649084 None 21 1.88E-14 0.081 
4 chr6:160023581-160024144 None 6 5.47E-12 -0.058 
5 chr19:29217858-29218774 None 7 4.20E-06 -0.088 
6 chr17:57915665-57918682 TMEM49; MIR21 12 6.97E-06 0.050 
7 chr9:124988720-124991047 LHX6 10 1.46E-05 0.070 
8 chr12:4916913-4919230 KCNA6 10 3.13E-05 0.051 
9 chr10:90985055-90985062 LIPA 2 4.51E-05 -0.076 
10 chr7:90895466-90896701 FZD1 5 8.30E-05 -0.063 
11 chr7:155150681-155151427 None 5 1.02E-04 0.056 
12 chr8:144631768-144631915 None 2 1.36E-04 0.054 
13 chr15:66947171-66947617 None 5 2.88E-04 0.086 
14 chr19:613111-613818 HCN2 4 3.51E-04 -0.051 
15 chr6:95220699-95221182 None 3 5.20E-04 0.057 
16 chr1:30240119-30240265 None 2 7.88E-04 -0.053 
17 chr8:637468-638330 ERICH1 4 7.88E-04 -0.063 
18 chr6:290800-293285 DUSP22 11 4.04E-03 0.089 
19 chr9:19378679-19379118 RPS6 2 4.15E-03 0.052 
20 chr19:48697722-48698632 None 3 6.54E-03 -0.055 
21 chr15:60987894-60987928 RORA 2 6.78E-03 0.090 
22 chr6:28664155-28664226 None 3 9.62E-03 -0.053 
23 chr8:216578-216788 None 4 1.02E-02 -0.094 
24 chr5:179740743-179741120 GFPT2 4 1.85E-02 0.092 
25 chr3:73045556-73045686 PPP4R2 2 2.91E-02 -0.086 
26 chr2:128168798-128168987 None 2 3.04E-02 0.050 
27 chr13:27295928-27296010 None 3 3.54E-02 0.063 
28 chr6:32490350-32490444 HLA-DRB5 2 4.17E-02 0.108 
29 chr5:118693725-118693764 TNFAIP8 2 4.39E-02 0.059 
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ABSTRACT
Alcohol dependence is a severe disorder contributing substantially to the global burden of disease.
Despite the detrimental consequences of chronic alcohol abuse and dependence, effective prevention
strategies as well as treatment options are largely missing to date. Accumulating evidence suggests that
gene-environment interactions, including epigenetic mechanisms, play a role in the etiology of alcohol
dependence. A recent epigenome-wide study reported widespread alterations of DNA methylation
patterns in alcohol dependent patients compared to control individuals. In the present study, we validate
and replicate one of the top ﬁndings from this previous investigation in an independent cohort: the
hypomethylation of GDAP1 in patients. To our knowledge, this is the ﬁrst independent replication of an
epigenome-wide ﬁnding in alcohol dependence. Furthermore, the AUDIT as well as the GSI score were
negatively associated with GDAP1 methylation and we found a trend toward a negative association
between GDAP1 methylation and the years of alcohol dependency, pointing toward a potential role of
GDAP1 hypomethylation as biomarker for disease severity. In addition, we show that the hypomethylation
of GDAP1 in patients reverses during a short-term alcohol treatment program, suggesting that GDAP1 DNA
methylation could also serve as a potential biomarker for treatment outcome. Our data add to the
growing body of knowledge on epigenetic effects in alcohol dependence and support GDAP1 as a novel
candidate gene implicated in this disorder. As the role of GDAP1 in alcohol dependence is unknown, this
novel candidate gene should be followed up in future studies.
KEYWORDS
Alcohol dependence;
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DNA methylation;
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Introduction
Causing approximately 3.3 million deaths every year (or 5.9%
of all deaths world-wide) and attributing to 5.1% of the global
burden of disease, harmful use of alcohol plays a decisive role
for health (WHO, 2014). Despite the detrimental consequences
of chronic alcohol abuse and dependence, effective preventive
strategies and treatment options are still less than optimal.
Genetic and environmental factors modulate susceptibility
to chronic alcohol abuse and alcohol dependence. Whereas
heritability estimates for alcohol dependence range between
40 and 60%, environmental and stochastic effects account
for the remainder of this variability.1-3 Accumulating evi-
dence suggests that genetic and environmental factors not
only act independently of each other but that also their inter-
actions are implicated in the etiology of alcohol depen-
dence.4-6 Among others, the interaction between genes and
environment is mediated by epigenetic mechanisms.7 The
major epigenetic mechanisms involve covalent modiﬁcations:
DNA methylation and posttranslational histone modiﬁca-
tions.8,9 Both mechanisms are important regulators of gene
expression.10 DNA is methylated at position 5 of the cytosine
pyrimidine ring, a reaction catalyzed by DNA methyltrans-
ferases (DNMTs). DNA methylation mainly occurs at the
cytosine of a CpG dinucleotide. These CpG sites are not
evenly distributed throughout the genome but are enriched
in regions called CpG islands. CpG islands overlap with the
promoter regions of 50 – 60% of human genes and are typi-
cally less methylated than CpG sites outside of CpG
islands.11 Methylation of CpG sites is usually correlated with
a decrease in gene expression.12,13
Initially, DNA methylation was believed to be established
during early embryonic development and to remain stable
afterwards. However, more recent research hints toward a
more complex pattern of transcriptional regulation through
DNA methylation and it is now known that DNA methylation
is a dynamic mechanism.14 DNA methylation patterns vary
over the lifetime of an organism and allow it to adapt to envi-
ronmental changes.15 Various diseases are associated with
altered epigenetic regulation and epigenetic mechanisms also
play an important role in many neuropsychiatric disorders, 16
such as depression,17 schizophrenia 18 and addictions 19 includ-
ing alcohol dependence.
Increased levels of homocysteine have been described in
alcohol dependent patients.20-22 Homocysteine is of impor-
tance for DNA methylation as it is metabolized to methio-
nine, which is then transformed into S-adenosyl methionine
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(SAM), the most important methyl group donor in verte-
brates.23 Consequently, elevated homocysteine levels were
associated with DNA hypermethylation in alcohol depen-
dent patients.24 In contrast to those ﬁndings, other studies
have reported that alcohol dependent patients lack the regu-
lation of methionine adenosyl transferase resulting in global
DNA hypomethylation.25,26
Several previous candidate-gene driven studies investigated
the interplay between alcohol consumption and DNA methyla-
tion. An impact of alcohol intake on the methylation state of
various genes, including monoamine oxidase A,27 dopamine
transporter,28 serotonin transporter,29 nerve growth factor 30
and, most recently, leptin 31 have been described.
To date, there are only few studies investigating the
inﬂuence of alcohol consumption on epigenetic mechanisms
at an epigenome-wide level. In these studies, a number of
genes were found to be signiﬁcantly differentially methyl-
ated epigenome-wide between alcohol dependent patients
and control individuals. The epigenetically differentially reg-
ulated regions included hyper- as well as hypo-methylated
genes in patients.32-34 The most recent study by Clark et al.
identiﬁed CNTN4 as a risk factor for alcohol use by exam-
ining the methylation status of approximately 27 million
autosomal CpG sites and comparing them to GWAS data.35
Earlier candidate-gene based studies investigating the inﬂu-
ence of therapeutic interventions on DNA methylation
reported decreasing homocysteine levels in alcohol depen-
dent patients during alcohol treatment,20,21,36,37 leading to
the hypothesis that DNA methylation levels also decrease
during alcohol treatment. However, candidate-gene driven
DNA methylation studies conducted thus far have resulted
in conﬂicting ﬁndings.28,30,38
To date, only one study has investigated the effects of an
alcohol treatment on the epigenome using a systematic
approach.32 No gene was epigenome-wide signiﬁcantly differ-
entially regulated when comparing the patients’ methylome at
the beginning of the alcohol treatment and after 4 weeks of
treatment. However, when comparing patients entering the
program and healthy control individuals, 56 genes reached epi-
genome-wide signiﬁcance after Bonferroni correction, among
them, GDAP1. This gene caught our attention, as it was the
most signiﬁcant ﬁnding within a promoter region of a charac-
terized gene product. GDAP1 was signiﬁcantly hypomethylated
in alcohol dependent patients compared to the control group.
GDAP1 is a member of the ganglioside-induced differentiation-
associated protein family. Mutations in GDAP1 have been
linked to Charcot-Marie-Tooth disease, a peripheral nerve dis-
order involving loss of muscle tissue.39,40 So far, no associations
of GDAP1 with alcohol dependence or other addictions have
been reported.
To clarify whether GDAP1 is indeed a novel epigenetic bio-
marker for alcohol dependence, we aimed to replicate the DNA
methylation status of GDAP1 in a cohort of 49 alcohol depen-
dent patients entering an alcohol treatment program and
37 healthy control individuals. In addition, we studied GDAP1
DNA methylation after 3 weeks of participating in an inpatient
alcohol treatment program to elucidate whether GDAP1 DNA
methylation could also serve as an epigenetic biomarker of
treatment response.
Results
Lower GDAP1 DNA methylation in patients
at the beginning of the alcohol treatment (T1) compared
to control individuals
The demographic characteristics as well as nicotine and alcohol
consumption of our cohort is provided in Table 1.
Control individuals and patients did not differ signiﬁcantly
in age (patients: 49 § 10.47 years, control individuals: 47 §
12.32 years; P D 0.3) or smoking behavior (control individuals:
16 § 10.99 cigarettes per day, patients: 20 § 10.93; P D 0.18).
AUDIT scores differed signiﬁcantly between control individu-
als (4.9 § 3.7; P D 5.1E-15) and patients (25.1 § 6.1) as well as
the GSI scores (0.16 § 0.13 for control individuals, 0.78 § 0.54
for patients; P D 1.7E-10).
For all 3 sites analyzed, DNAmethylation levels between control
individuals and patients at T1 differed signiﬁcantly (Table 2 and
Fig. 1). For cg23779890 / site 1, the CpG site identiﬁed by Philibert
et al.,32 DNA methylation levels were as follows: 7.8 § 0.2 in con-
trol individuals, 6.6 § 0.3 in patients, P D 0.001. For site 2, DNA
methylation levels were 4.0 § 0.1 in control individuals and 3.6 §
0.1 in patients, PD 0.015. For site 3, DNAmethylation levels were
2.1§ 0.1 in control individuals and 1.8§ 0.1 in patients, PD 0.012.
Mean DNA methylation across all 3 sites differed signiﬁ-
cantly between control individuals and patients (control indi-
viduals: 4.6 § 0.1, patients: 4.0 § 0.2; P D 0.001).
Since the DNA methylation levels of each site were highly
correlated with the mean DNA methylation level across all sites
(site 1: rs D 0.979, P D 2.0E-82; site 2: rs D 0.938, P D 1.4E-55;
site 3: rs D 0.892, P D 4.0E-42), we decided to use the mean
DNA methylation levels for further analyses.
First, comparing control individuals and patients at T1, the
mean DNA methylation level was signiﬁcantly negatively associ-
ated with the GSI score (rs D ¡0.2066, P D 0.016), and AUDIT
Score (rs D ¡0.2041, P D 0.009). Furthermore, a trend toward a
negative association between themean DNAmethylation level and
the years of dependency (rs D 0.266, P D 0.08) was observed. We
did not ﬁnd any association between the DNA methylation levels
and the amount of drinks consumed daily in theweek before hospi-
tal admission (rsD¡0.1038, PD 0.35).
Alcohol treatment signiﬁcantly inﬂuences GDAP1 DNA
methylation levels in alcohol dependent patients
After three weeks of alcohol treatment (T2), DNA methylation
levels at all 3 sites were increased (Fig. 1, Table 3): 7.3 § 0.3
Table 1. Characterization of patients and control individuals. Errors are given as
standard deviation (SD). Amount of drinks is the standardized unit originating
from the AUDIT questionnaire.
Control individuals Patients P-value
Total N 37 49
Age (years) 47 § 12.32 49 § 10.47 0.30
Smokers (% of total) 29 (78%) 38 (79%) 0.93
Cigarettes smoked daily 16 § 10.99 20 § 10.93 0.18
Days since last drink 2.9 § 6.9
Amount of drinks consumed
daily one week before
hospital admission
17 § 13.1
Years of alcohol dependency 12.3 § 9.9
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(site 1, P D 0.001), 3.8 § 0.1 (site 2, P D 0.033) and 2.0 § 0.1
(site 3, P D 0.001). Again, the mean DNA methylation across
these sites differed signiﬁcantly (4.4 § 0.2, P D 0.001)
from the values of patients at T1 (4.0 § 0.2) and were highly
correlated with each other (site 1: rs D 0.972, P D 4.6E-21;
site 2: rs D 0.901, P D 9.1E-13; site 3: rs D 0.877,
P D 2.2E-11). In addition, the GSI score decreased signiﬁ-
cantly (0.78 § 0.54 vs. 0.48 § 0.49, P D 0.008, N D 30), as
well as the OCDS score (3.93 § 1.32 vs. 2.71 § 0.96,
P D 2.1E-5, N D 33).
Comparing the mean DNA methylation across all 3 sites
between the control individuals and patients at T2, none of the
DNA methylation levels differed signiﬁcantly (site 1: P D 0.098;
site 2: P D 0.244; site 3: 0.377; mean: P D 0.167).
The exclusion of 8 patients who had been abstinent for more
than 3 d before hospital admission led to a diminishment of the
days since the last drink from 2.9 § 6.9 d to only 1.3 § 0.8 d.
Furthermore, it enhanced the observed effect of differential
GDAP1 methylation between control individuals and patients
at T1. At T2, this only had a moderately positive effect (see
Table S1).
Discussion
By conducting pyrosequencing of 3 adjacent CpG sites in
GDAP1, including cg23779890, we were able to replicate the
ﬁnding of signiﬁcant differences in DNA methylation between
alcohol dependent patients and matched control individuals
previously reported by Philibert et al.32 In addition, we identi-
ﬁed signiﬁcant differences between GDAP1 DNA methylation
levels in patients at the day of hospital admission (T1) and after
Table 2. DNA methylation levels, AUDIT and GSI scores for control individuals vs.
patients at T1. DNA Methylation level errors are given as standard error of the
mean (SE), questionnaire score errors are given as standard deviation (SD).
Control individuals Patients at T1 P-value
Site 1 (cg23779890) 7.8 § 0.2 6.6§ 0.3 0.001
Site 2 4.0 § 0.1 3.6§ 0.1 0.015
Site 3 2.1 § 0.1 1.9§ 0.1 0.012
Mean DNA methylation
(sites 1 – 3)
4.6 § 0.1 4.0§ 0.2 0.001
AUDIT score 4.9 § 3.7 25.1§ 6.1 5.1E-15
GSI score 0.16 § 0.13 0.78§ 0.54 1.7E-10
Figure 1. DNA methylation levels at (A) site 1 / cg23779890, (B) site 2 and (C) site 3 for control individuals, patients at T1 and patients at T2. Signiﬁcant differences are
indicated with  (P  0.05) and  (P  0.001).
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3 weeks of attending an inpatient alcohol treatment program
(T2). Furthermore, the AUDIT score as well as the GSI score at
T1 were negatively associated with the DNA methylation levels
and we found a trend toward a negative association between
the DNA methylation levels and the years of alcohol depen-
dency, but not with the amount of drinks consumed in the
week before hospital admission. Our study thus provides addi-
tional evidence supporting the hypothesis that GDAP1 DNA
methylation could serve as new biomarker for the severity of
alcohol dependence.
In contrast to the hypothesis of increased DNA methylation
levels in alcohol dependent patients due to higher levels of
homocysteine,24 our results, as well as the previous results from
Philibert et al. 32 show a hypomethylation of the GDAP1 gene
in patients compared to control individuals. This was surpris-
ing, but as we did not measure homocysteine levels in our study
samples, we can neither support nor contradict a potential cor-
relation between homocysteine levels and DNA methylation of
the GDAP1 gene promoter. Nevertheless, other studies did not
ﬁnd a correlation between homocysteine and global DNA
methylation, and some did ﬁnd a hypothesis-opposing out-
come: with higher homocysteine levels in their samples, global
DNA methylation was decreased.41 Other studies speculate that
the missing regulation of the methionine adenosyl transferase
in alcohol dependent patients results in global DNA hypome-
thylation.25,26 A recent study speciﬁcally investigating the role
of homocysteine in altered DNA methylation in 363 alcohol
dependent patients also found no correlation between homo-
cysteine and global DNA methylation.42 Further studies are
therefore necessary to clarify the relationship between homo-
cysteine levels and GDAP1 DNA methylation.
Furthermore, we observe that increased severity of alcohol
dependence in patients, assessed by the AUDIT score, as well
as the GSI score, is associated with lower GDAP1 DNA methyl-
ation. However, we did not ﬁnd a correlation between the
amount of alcohol consumed one week before admission to the
hospital and GDAP1 DNA methylation. As the exact amount
of alcohol consumed one week before hospital admission does
not affect GDAP1 DNA methylation, but rather the intensity
and time span of alcohol dependence, GDAP1 DNA methyla-
tion could serve as an indicator of long-term and severe alcohol
dependence rather than for short-term alcohol exposure.
Whereas Philibert et al. did not identify signiﬁcant differen-
ces in GDAP1 DNA methylation in patients between T1 and
T2, our results show an increase in DNA methylation levels in
patients at T2, which no longer differed from the levels in con-
trol individuals. Our ﬁnding therefore supports the hypothesis
of DNA methylation as a reversible process and suggests that
DNA methylation levels return to their previous state, if the
environmental condition underlying the epigenetic alteration—
in this case alcohol dependence—is amended. However, to
prove this hypothesis, it would be necessary to perform a longi-
tudinal study and compare GDAP1 DNA methylation in
patients before and after the onset of the disease. In our study,
we only included patients after disease onset (mean years of
dependency: 12.3 § 9.9 years). After three weeks of attending
an inpatient alcohol treatment program, the GSI score as well
as the OCDS score, a measure of craving severity, decreased sig-
niﬁcantly in our patient cohort, suggesting a positive therapy
outcome. Questionnaires are the most common means to assess
these traits but are not an objective measure as they can be sub-
jectively biased. The reversion of GDAP1 DNA methylation
levels during abstinence could therefore serve as a biological,
more objective indicator of a positive therapy outcome.
Although DNA methylation percentages in our study did
deviate from the ones reported by Philibert and colleagues,32
we are able to replicate and validate the effect of alcohol depen-
dence on GDAP1 DNA methylation. Philibert et al. found the
mean DNA methylation level of cg23779890 to be 19.4% in
patients and 24.3% in control individuals. We measured DNA
methylation levels of 6.6% and 7.8%, respectively. These differ-
ences could be explained as follows.
One major difference between these studies is the source of
material. Philibert and colleagues used mononuclear cells,
whereas we used DNA prepared from whole blood. Whole
blood is a heterogeneous mixture of different cell-types and
blood composition varies from individual to individual and is
depending on numerous factors such as age, sex, and individual
health status. This is of importance as DNA methylation pat-
terns are cell-type speciﬁc and could therefore explain the dif-
ferences in DNA methylation levels between our study and the
study by Philibert et al.32
The use of whole blood could be seen as a limitation of our
study. However, we have explicitly chosen to investigate
GDAP1 DNA methylation in whole blood to serve as an epige-
netic biomarker for alcohol dependence and as a potential
gauge of the therapy efﬁcacy in a clinical setting. To be suitable
as a biomarker, the study material needs to be easy and cost
effective to obtain. The preparation and use of mononuclear
cells for clinical diagnostics is impossible, as it is very time-con-
suming and labor-intensive in addition to being more expen-
sive than the usage of whole blood.
In addition, as both the Illumina’s 450K Chip as well as the
pyrosequencing approach have systematic biases the differences
could also be explained by the different methods used. As the
overall congruency between Illumina’s 450K Chip and pyrose-
quencing data is good, there are however speciﬁc sites where a
direct translation from b-values originating from the Chip
analysis to DNA methylation levels measured by pyrosequenc-
ing is difﬁcult.43 These include, but are not limited to non-spe-
ciﬁc and cross-hybridizing probes, which represent a
combination of multiple loci and therefore can elevate readings
of low methylation or diminish readings of high methylation,
biasing the results.44 Another well-known limitation of pyrose-
quencing is ampliﬁcation bias. To account for this and to pre-
vent batch effects, the samples were run at least in duplicates
and they were assigned to different positions on different plates.
Table 3. DNA methylation levels, OCDS and GSI scores for patients at T1 vs.
patients at T2. DNA Methylation level errors are given as standard error of the
mean (SE), questionnaire score errors are given as standard deviation (SD).
Patients at T1 Patients at T2 P-value
Site 1 (cg23779890) 6.6 § 0.3 7.3 § 0.3 0.001
Site 2 3.6 § 0.1 3.8 § 0.1 0.033
Site 3 1.9 § 0.1 2.0 § 0.1 0.001
Mean DNA methylation(sites 1 – 3) 4.0 § 0.2 4.4 § 0.2 0.001
OCDS score 3.93§ 1.32 2.71 § 0.96 2.1E-5
GSI score 0.78§ 0.54 0.48 § 0.49 0.008
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However, the overall effect in DNA methylation changes
between patients at T1 and control individuals in both studies
is very similar despite being obtained in 2 distinct cohorts using
different methods (450K Chip analysis vs. pyrosequencing) as
well as different sources of DNA: Philibert et al. found a 4.9%
higher DNA methylation in control individuals compared to
patients; our data show a 1.2% higher DNA methylation. These
data indicate that indeed GDAP1 DNA methylation levels
obtained from whole blood are usable as potential epigenetic
biomarkers of alcohol dependence severity. Although the dif-
ferences in DNA methylation are quite small, the fact that they
can be found in different populations, different tissue as well as
with different analytical methods suggests that GDAP1 DNA
methylation could serve as biological predictor of alcohol
dependence, especially in combination with epigenetic data of
other genes of known inﬂuence. Unfortunately, we were not
able to collect a second sample after 3 weeks from those
patients, who did not complete the alcohol treatment. Without
having obtained the DNA methylation levels for this group, we
can only speculate that GDAP1 DNA methylation could also
serve as a biomarker for treatment outcome. Measuring DNA
methylation levels at a second time point from patients, who
do not complete the alcohol treatment, should be taken into
consideration in future studies.
In contrast to Philibert et al., we used a slightly different
matching strategy: The cohort used for this study only consists
of Caucasian men, and patients and control individuals were
matched for age and smoking behavior. The cohort investigated
by Philibert et al. is more heterogeneous, consisting of both
sexes and different ethnicities. Furthermore, 27 patients were
daily smokers, whereas only one control individual was a daily
smoker. This is problematic, because smoking has a major
inﬂuence on DNA methylation patterns.45 The authors take
this limitation of their study into consideration by comparing
the overlap of their 10000 most signiﬁcant probes to the
910 epigenome-wide signiﬁcant genes found by Dogan et al.,
who evaluated the effect of smoking on DNA methylation.45
Only 22 signiﬁcant hits were overlapping between the 2 studies,
leading Philibert et al. to the conclusion that the effects they are
reporting are indeed due to alcohol consumption, and are not
biased by differences in smoking behavior. However, this
approach is based on the assumption that Dogan et al. were
able to identify all genes epigenetically altered by smoking,
which is highly unlikely. Furthermore, this strategy does not
take into account potential overlapping effects of both smoking
and alcohol consumption, which displays a high comorbidity
and would therefore have to be further evaluated.
As already mentioned, no associations between the outer mito-
chondrial membrane protein GDAP1 and alcohol dependence
have been reported thus far. Mutations in GDAP1 cause Charcot-
Marie-Tooth (CMT) disease, a hereditary motor, and sensory neu-
ropathy.46 The 2 major causes leading to CMT disease are muta-
tions in PMP22 andMFN2, which directly affect the myelin sheath
and the axon.47,48 Mutations in GDAP1 are associated with
decreased mitochondrial ﬁssion activity (recessively inherited) or
an impairment of mitochondrial fusion (dominantly inher-
ited).39,40, 49 The expression of dominantly inheritedmutated forms
of GDAP1 lead to increased production of reactive oxygen species
(ROS).50 Furthermore, wild type GDAP1 has been reported to
protect against oxidative stress.51 As the production of ROS also is
a direct effect of alcohol intake,52 this could be a potential link
explainingGDAP1 hypomethylation in alcohol dependent patients:
DNA hypomethylation should lead to increased expression and
consequently increased protein production in alcohol dependent
patients. Therefore, GDAP1 overexpression could counteract and
compensate for the increased oxidative stress in alcohol depen-
dence. This hypothesis is supported by the fact that DNAmethyla-
tion levels rise after 3 weeks of alcohol treatment. In this time
period, oxidative stress in alcohol dependent patients should be
dramatically reduced. However, as we neither measured GDAP1
expression, nor GDAP1 protein levels or the levels of ROS, this
hypothesis should be followed up in subsequent studies. Further
links betweenCMT and alcohol dependence are provided by recent
studies, showing that a triple-therapy with a combination of nal-
trexone, baclofen, and sorbitol (PXT3003) can improve health of
patients suffering from CMT disease.53,54 While PXT3003 was
shown to downregulate PMP22 mRNA expression and improve
myelination as well as axonal regeneration,53 both naltrexone and
baclofen are also used (partly off-label) to treat alcohol depen-
dence.55 Acting as an opioid antagonist (naltrexone) and a GABA-
B-receptor agonist (baclofen), respectively, these drugs reduce the
rewarding effects of alcohol and inhibit dopaminergic neurotrans-
mission.56 Whether GDAP1 is also inﬂuenced by naltrexone and/
or baclofen requires investigation.
The GDAP1 gene is regulated by the transcription factor
YY1.57 Up to date, there is no evidence linking YY1 to alcohol
dependence. However, other putative transcription factor bind-
ing sites include the binding sites of EGR1 and ZNF143, among
others, as analyzed with JASPAR.58 For both transcription fac-
tors, a potential link to alcohol dependence, such as alcoholic
fatty liver disease 59 or the regulation of aldehyde reductase 60
has been previously reported. The lack of functional data is a
limitation of our study. Therefore, future studies are needed to
better understand the regulation of GDAP1 as well as its func-
tion in the context of alcohol dependence and to investigate the
impact of altered DNA methylation on gene expression.
In conclusion, in the present study we were able to validate
and replicate the ﬁnding of GDAP1 being signiﬁcantly hypome-
thylated in alcohol dependent patients compared to healthy
control individuals, which was previously discovered in an epi-
genome-wide association study.32 Furthermore, we show that
these differences in DNA methylation diminish after 3 weeks of
abstinence, leading us to the conclusion that GDAP1 DNA
methylation could serve as a possible epigenetic biomarker for
severity of alcohol dependence and potentially for treatment
outcome. Our data add to the growing body of knowledge on
epigenetic effects in alcohol dependence and support GDAP1
as a novel candidate gene implicated in alcohol dependence.
However, future studies are needed to replicate our ﬁnding of
epigenetic changes in GDAP1 during alcohol treatment in inde-
pendent cohorts, as well as to clarify potential mechanisms of
action.
Subjects & methods
This sample was comprised of 49 male patients (mean age
49.14 § 10.47 years) with a diagnosis of alcohol dependence
according to the fourth edition of the Diagnostic and Statistical
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Manual of Mental Disorders (DSM-IV) participating in a 3- or
6-week alcohol treatment program at the Clinic for Psychiatry
and Psychotherapy, Tuebingen. Subjects with any other addic-
tion except nicotine have been excluded, as well as subjects
with any other psychiatric comorbidity necessitating psychiat-
ric medication. Except for 8 patients, the last exposure to alco-
hol before entering the study had not exceeded 72 h. For the
ﬁrst days of detoxiﬁcation, clomethiazole was administered if
necessary. Population-based male control individuals (n D 37,
mean age 47.41 § 12.32 years) were recruited from the city of
Tuebingen, Germany and the surrounding area. Control indi-
viduals were matched for age and smoking behavior. Pheno-
typic information about patients and control individuals was
obtained by self-administered questionnaires. The following
questionnaires were used in patients: Alcohol consumption was
assessed using the AUDIT,61 alcohol craving using the OCDS
62 and the global distress level (GSI) using the SCL-90-R.63 The
SCL-90-R and OCDS were repeated after 21 d of detoxiﬁcation
(T2). Control individuals were screened for problematic alcohol
intake using the AUDIT questionnaire, and control individuals
with an AUDIT-Score > 15 were excluded, as a higher value is
suggestive for alcohol dependence.28 The SCL-90-R question-
naire was used in control individuals as well, and in addition,
demographic information and health status of both—patients
and control individuals—was assessed. All subjects were
Caucasian and provided written informed consent prior to par-
ticipation. The study was approved by the ethics committee of
the University of Tuebingen and was conducted in accordance
with the Declaration of Helsinki.
Ethylenediaminetetraacetic (EDTA) peripheral venous
blood samples were taken from all patients immediately
after hospital admission (T1). After 21 d (§ 2 d) of treat-
ment (T2), a second EDTA-blood sample was taken from
the 33 patients (mean age 48.7 § 10.92 years) who
remained in the program (drop-out rate: 33%). EDTA-blood
from control individuals was drawn immediately after study
inclusion. Blood samples were instantly frozen and kept
at ¡80C until further usage. DNA was extracted using the
QIAamp DNA Blood Maxi Kit (Qiagen). Genomic DNA
(500 ng) was bisulﬁte converted using the EpiTect Fast
Bisulﬁte Conversion Kit (Qiagen) according to the manufac-
turer’s protocol with the following adjustments: incubation
steps at 60C were prolonged to 15 min (instead
of 10 min); converted DNA was eluted in 20 ml instead of
15 ml and stored at ¡20C until analysis.
Pyrosequencing was performed as follows: A 166 bp frag-
ment covering the TSS200 region of GDAP1 and partially
overlapping the transcription start site was ampliﬁed by PCR
from 2 ml bisulﬁte-treated DNA using the PCR Primer Set
from the PyroMark CpG Assay GDAP1 (PM00035399) and
the PyroMark PCR Kit (both Qiagen) according to manufac-
turer’s protocol. The CpG Assay GDAP1 covers 3 CpG sites
located within chromosome 8 (site 1 located at 75,262,523,
95 bp upstream of the TSS; site 2 located at 75,262,532, 86 bp
upstream of the TSS; and site 3 located at 75,262,534, 84 bp
upstream of the TSS) and includes the CpG site cg23779890
(site 1) which has been previously implicated by Philibert
et al.32 The 3 CpG sites are part of a larger CpG island includ-
ing 48 CpG sites (chr8:75,262,522-75,263,044).
Cycling conditions were as follows: 95C for 15 min; 94C
for 30 s, 56C for 30 s, 72C for 30 s (45 cycles); 72C for
10 min. To detect potentially biased ampliﬁcation of differen-
tially methylated fragments, DNA samples with known methyl-
ation levels (0%, 25%, 50%, 75%, and 100%) were included as
controls (EpiTect Control DNA, Qiagen) in the ampliﬁcation
and the pyrosequencing reaction.
PCR products and a no template control were visualized on
a 2% agarose gel to verify successful ampliﬁcation and speciﬁc-
ity of the products. Processing of the PCR amplicons for the
pyrosequencing analysis was performed in accordance with the
manufacturers protocol and PCR products were then pyrose-
quenced using the PyroMark Q24 system (Qiagen) and the
sequencing primer from the PyroMark CpG Assay GDAP1
(PM00035399). The percentage of methylation at each of the
3 CpG sites analyzed was quantiﬁed using the PyroMark Q24
software version 2.0.6 (Qiagen). Pyrosequencing was performed
in duplicates. To avoid plate effects, samples from patients and
control individuals were mixed on each plate and the samples
were randomly assigned to different wells for the 2 sequencing
runs. For quality control the coefﬁcient of variance (CV) was
calculated. For the 33 samples (18 control individual samples,
14 patient samples at T1 and 1 patient sample at T2) where the
CV between 2 runs for any site was  0.3, a third measurement
was obtained. The outlier was eliminated from further analysis,
and only the 2 remaining values were used. Using this approach
led to a maximum variation of 2.02%. Typically, an intra-sam-
ple variation of  3% is considered reliable.
Statistical analysis was conducted using SPSS version 21.0
(IBM). Each site was examined individually. DNA methylation
levels were not normally distributed according to the Shapiro-
Wilk test. Hence, non-parametric test methods were applied.
Differences in the percentage of DNA methylation between the
patient group and the control group were analyzed using the
Mann-Whitney U test. For identifying differences in DNA
methylation, GSI score, and OCDS score between the 2 time
points T1 and T2 of the patients, the Wilcoxon test was used.
Correlations between continuous variables were tested using
the Spearman correlation test. A signiﬁcance level of P  0.05
was considered signiﬁcant.
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Table S1: Comparison of p-values before and after the exclusion of eight previously abstinent 1 
patients. Values are p-values. 2 
control individuals vs. patients at 
T1 
patients at T1 vs. patients at T2 
before 
exclusion 
after exclusion before 
exclusion 
after exclusion 
N 49 patients at 
T1 
41 patients at 
T1 
33 patients at 
T2 
31 patients at 
T2 
Site 1 0.001 2.5E-4 0.001 0.001 
Site 2 0.015 0.01 0.033 0.031 
Site 3 0.012 0.005 0.001 0.001 
Mean DNA 
methylation 
(sites 1 - 3) 
0.001 0.001 0.001 0.001 
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the epigenome-wide analysis by pyrosequencing and further replicated two of them in an independent 
Ƥơ͸ and ͹ǤƤ
to show widespread DNAm variation in a disease-relevant blood cell type and implicates ͸ and 
͹ DNAm as promising blood-based candidates to follow up in future studies.
Alcohol dependence (AD) is a severe disorder that has long-lasting detrimental consequences, resulting in con-
siderable health, economic and societal burden. According to the World Health Organization, alcohol related 
diseases account for approximately 3.3 million deaths per year (WHO, 2014). Although this number is alarmingly 
high, studies indicate that problematic drinking behaviour still is underestimated1. To date, treatment options are 
limited and the effectiveness of existing alcohol treatment programs is often less than optimal or difficult to assess, 
warranting a need for improvement.
The pathogenesis of AD is complex and includes genetic as well as non-genetic factors. Evidence is emerging 
that the interaction between underlying genetic factors and environmental stimuli (gene x environment, GxE) 
in particular plays a major role in addiction-related disease states2–4. Such findings have prompted considerable 
inquiry into the biological basis of GxE influences, with epigenetic regulation providing one of the most compel-
ling candidate mechanisms for the mediation of GxE effects5, 6.
One of the most frequently studied epigenetic mechanisms is DNA methylation (DNAm), which 
involves the covalent addition of a methyl group to the 5′ position of a cytosine, primarily in the context of 
a cytosine-phosphate-guanine (CpG) dinucleotide. CpG dinucleotides are especially prevalent in CpG islands, 
genomic regions of approximately 1000 base pairs (bp) with a CG content greater than 50%7. CpG islands are 
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associated with 50–70% of human gene promoters and increased DNAm in these regions is generally corre-
lated with a decreased transcription of the respective gene8, 9. Furthermore, methylated regions adjacent to CpG 
islands, called CpG island shores (up to 2 kb in either direction) or shelves (from 2 to 4 kb in either direction), may 
contribute to and potentiate epigenetic effects on gene expression10–12. In recent years, there has been increasing 
appreciation for the complexity of the relationship between DNAm and gene expression regulation, which tends 
to be highly dependent on genomic context9, 13. DNAm profiles of genetic regions can vary substantially between 
different cell types14. It has been shown that after tissue origin, cellular heterogeneity within a tissue is a major 
driver of DNAm variance, highlighting the need to account for cellular composition in DNAm analyses15, 16.
Several biological factors including age17, sex18 and ethnicity19 also have a profound impact on DNAm pat-
terns. In addition, a number of lifestyle-based environmental exposures, including smoking20–23 and alcohol con-
sumption24–36, are associated with variation in DNAm. In particular, DNAm alterations in AD patients have been 
documented in a number of epigenetic studies in human populations. For example, candidate gene analyses 
reported differential DNAm of the dopamine30 and serotonin transporters32, the nerve growth factor NGF27, lep-
tin28 and most recently GDAP125 in AD patients compared to healthy controls. In the context of epigenome-wide 
association studies (EWAS), previous studies found widespread AD-associated DNAm differences at single sites, 
differentially methylated regions (DMRs)26, 33–35 and in “bulk” DNAm, representing mean global total levels 
of DNAm29, 36. One study assessed DNAm alterations in peripheral blood mononuclear cells (PBMCs) of AD 
patients participating in a short-term alcohol treatment program compared to healthy controls, and reported dif-
ferential methylation at 56 CpG sites in patients prior to treatment compared to controls. Although no statistically 
significant DNAm differences were observed in patients before and after the alcohol treatment program, 49 of the 
56 differential sites reverted back in patients post-treatment to levels similar to controls31. Together, these previ-
ous studies identified a multitude of AD-associated differentially methylated sites, however, they did not account 
for cell type heterogeneity in their analyses, thereby potentially resulting in associations that are confounded by 
inter- and intra-individual differences in cellular composition. Most recently, a study involving 13,317 partici-
pants from 13 distinct cohorts analysed DNAm profiles in monocytes and whole blood. This analysis, which was 
adjusted for cell composition, revealed hundreds of AD-associated differentially methylated CpG sites29.
Although all these previous studies support a potential link between DNAm variation and AD, a number of 
questions have yet to be explored: I) Are there signatures of AD in a disease-relevant blood cell type? II) Does 
treatment result in reversion of differential DNAm back to the levels found in controls? III) Importantly, can such 
AD-associated differential DNAm be replicated in independent cohorts, signifying the robustness of the iden-
tified genome-wide hits, and IV) Can the differential DNAm from a purified blood cell type also be detected in 
whole blood samples, indicating the potential relevance of these associations in other blood cell types?
To address these questions, we assessed genome-wide DNAm profiles of purified CD3+ T-cells of a 
well-characterized cohort of long-term chronic AD patients participating in a clinical 3-week alcohol treatment 
program, along with the profiles of healthy controls closely matched for sex, age, ethnicity and smoking behav-
iour. We restricted our analyses to T-cells due to the known effects of chronic alcohol abuse in modulating the 
number, activity and relative subtype abundance levels of these immune cells37. For example, short-term binge 
drinkers as well as chronic AD patients exhibit a reduced number of peripheral T-cells38. In addition, a shift 
from CD4+ and CD8+ naïve T-cells towards memory T-cells is observed in AD patients39. Furthermore, alcohol 
consumption influences T-cell activation, leading to elevated numbers of activated CD8+ T-cells, which may con-
tribute to chronic inflammation37, 40. For these reasons, heightened susceptibility to infections, including tuber-
culosis, pneumonia and HIV is observed in those patients37, 41. T-cells have also been used previously in similar 
epigenetic studies due to their regulatory function in neuroimmune mechanisms42, 43. Furthermore, by comparing 
the patients before and after 3 weeks of participating in a clinical alcohol treatment program, we sought to identify 
differentially methylated sites that may play a potential role in alcohol withdrawal and early recovery. In order 
to test whether our findings were robust, we validated four of our top-ranked hits by pyrosequencing, replicated 
the top-ranking hits in an independent second cohort of AD patients and matched controls and additionally 
confirmed the top-ranking hits in whole blood DNA of our cohort samples.
Results
Study cohorts and DNA methylation array normalization. To identify AD-associated DNAm var-
iation, we utilized a discovery and replication cohort of AD patients and healthy controls, who were closely 
matched for age, sex and smoking behaviour. Demographic and AD-relevant characteristics as well as AUDIT 
and GSI scores of both cohorts are provided in Table 1a and b. To measure the effectiveness of the 3-week alcohol 
treatment program, we compared both GSI and OCDS scores in the discovery cohort at the beginning and after 
treatment. We found that both values decreased significantly, indicating a reduced alcohol craving and a better 
overall psychological well-being post-treatment (Table 1c).
In order to assess the association of AD with genome-wide DNAm in our discovery cohort, we measured 
site-specific DNAm at over 450,000 CpGs using the Illumina 450 K array. To test for potential cellular heteroge-
neity in the bead-purified CD3+ T-cell samples, we used the Houseman blood deconvolution algorithm to esti-
mate cell-type proportions, observing up to 32% of contaminating non-T-cell DNA in a fraction of our samples, 
although these proportions were not correlated with group status (Supplementary Figure S1). Regression-based 
adjustment of 450 K data resulted in the removal of these cell type associations as assessed by PCA (Supplementary 
Figure S2). The adjusted dataset thereby represented DNAm profiles from T-cells whose inter-individual cell type 
differences had been normalized to the best of our abilities for subsequent analyses.
Identification of AD-associated differential DNAm. Based on site-specific analyses of the T-cell 
DNAm array profiles, we identified 59 differentially methylated CpG sites between patients (T1) and controls 
with DNAm differences (Δ-beta) of at least 5% to increase the likelihood of biological relevance (FDR < 0.1). Of 
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these 59 hits, 28 sites showed higher methylation, while 31 sites had lower methylation in patients compared to 
controls. Differences in DNAm ranged from 5 to 14% (Fig. 1a). The top 10 hits, ranked by Benjamini-Hochberg 
(BH)-adjusted P-value significance, are listed in Table 2a. A complete list of all 59 significant hits (FDR < 0.1) is 
provided in Supplementary Table S1. The top-ranked hit (cg18752527) exhibited a DNAm difference of 6.6% and 
was located within the intragenic region of the HECW2 gene.
In addition to single CpG sites, we identified 29 significant DMRs (FDR < 0.01, Δ-beta > 5%) using 
DMRCate. These DMRs contained 153 CpG sites, of which 8 were also identified as differentially methylated in 
the site-specific analysis between controls and patients (T1) (Supplementary Table S2). Interestingly, 4 of these 
overlapping 8 hits were in the SRPK3 gene region (Fig. 1b).
ǦǦƤǤ To identify differentially methylated sites 
potentially playing an important role in alcohol withdrawal and early recovery in AD patients, we compared 
genome-wide T-cell DNAm profiles of patients before (T1) and after 3 weeks (T2) of participation in an alcohol 
treatment program. Using paired testing in our site-specific analyses, we identified 48 differentially methylated 
sites between patients (T1) and patients (T2), all of which showed increased methylation at T2 ranging from 5 to 
12% difference (FDR < 0.1, Δ-beta > 5%) (Fig. 1c, Supplementary Table S3). The top 10 hits are listed in Table 2b. 
Utilizing the same threshold as before, we did not observe any DMRs in patients before and after treatment.
ǦơǤ To examine whether AD-associated 
DNAm is influenced by a 3-week alcohol treatment program, we assessed DNAm levels in patients post-treatment 
at the 59 sites identified in the analysis comparing controls and patients (T1). After the treatment (T2), the 
DNAm levels of 7 out of 59 sites reverted back to a level where they no longer significantly differed from controls 
(Fig. 1d). Based on paired testing, we determined that these 7 sites were indeed differentially methylated between 
patients (T1) and patients (T2). Moreover, 32 CpG sites showed a trend to revert back, though not significant at 
an FDR < 0.1. The DNAm levels of the remaining 20 sites did not change from T1 to T2.
ơǤ Given the unidirectional change in 
our site-specific analysis of patients before and after treatment, particularly at AD-associated sites which showed 
post-treatment reversion, we next examined if this trend was related to AD-associated differences in mean global 
DNAm. Here we defined mean global DNAm as the calculated average of DNAm values across all sites in each 
sample. We found that although the result was only nominally statistically significant, prior to the alcohol treat-
ment (T1), mean global DNAm was lower in patients compared to controls (P = 0.048, Mann-Whitney U test). 
However, at the end of treatment (T2), global DNAm of the patients approximated the levels seen in controls and 
no longer differed significantly from controls (Fig. 2a). This finding was consistent with the unidirectional differ-
ences, in that all significant sites between patients before and after treatment showed increased methylation at T2 
in the site-specific analysis, and supported the observed post-treatment reversion of AD-associated sites. Of note, 
these differences in mean global DNAm are unlikely to be driven by batch effects or other sources of technical 
variation due to the fact that all samples were run in a randomized manner on the same set of arrays.
ơÃǦǤ To evaluate if there were differ-
ences in underlying T-cell subtypes between the groups, we estimated abundance measures of additional blood 
a) Discovery study cohort b) Replication study cohort
Controls 
(N = 23)
Patients 
(N = 24)
P-
value
Controls 
(N = 12)
Patients 
(N = 13)
P-
value
age 46.9 ± 10.3 47.5 ± 10.1 0.8 45.3 ± 16.2 50.9 ± 9.1 0.4
active smokers 18 (78%) 19 (79%) 0.9 8 (67%) 9 (69%) 0.9
cigarettes per day 13.8 ± 12.6 15.2 ± 10.7 0.7 8.9 ± 8.0 10.5 ± 9.4 0.7
Years of alcohol dependence 10.6 ± 9.4 14.6 ± 11.7
Days since last drink before 
hospital admission 1.2 ± 0.6 0.3 ± 0.4
Standard drinks consumed 
each day in the week before 
hospital admission
13.7 ± 8.3 19 ± 11.4
AUDIT 5.9 ± 3.8 24 ± 6.5 4E-15 2.8 ± 2.3 28.0 ± 4.9 3E-14
GSI 0.15 ± 0.14 0.72 ± 0.45 6E-07 0.10 ± 0.09 0.11 ± 0.10 0.9
c) Results after 3-week alcohol treatment in the discovery cohort
Patients (T1) Patients (T2) P-value (paired testing)
GSI 0.72 ± 0.45 0.41 ± 0.52 0.036
OCDS 19.3 ± 6.6 12.0 ± 4.9 3E-05
Table 1. Description of a) the discovery study cohort, b) the replication study cohort and c) results after 3-week 
alcohol treatment program in the discovery cohort. Errors are given as standard deviation. Abbreviations: 
AUDIT, alcohol use disorder identification test; GSI, global severity index; OCDS, obsessive compulsive 
drinking scale.
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cell subsets using an advanced blood analysis option for an epigenetic clock prediction tool44 on our T-cell 450 K 
profiles. We observed that the predicted abundance levels of both CD4+ and CD8+ naïve T-cell subsets signifi-
cantly increased post-treatment in AD patients (FDR < 0.01, Wilcoxon signed rank test) (Fig. 2b). However, the 
abundance of these naïve T-cell subtypes was not statistically significantly different between controls and patients 
at either time point.
ǦơǤ To verify the 
results from the 450 K dataset, we selected two top-ranking differentially methylated sites between controls and 
patients (T1) (cg18752527 in the HECW2 gene and cg07280807 in an intergenic region) for validation using 
pyrosequencing as an independent readout of DNAm measures. We additionally validated two promoter CpGs 
of SRPK3 (cg16529483 and cg24496423) since differential methylation in the SRPK3 gene region was found to 
be a robust finding in our DMRcate analyses. We were able to confirm significant differences between controls 
and patients (T1) at all 4 sites, as shown in Fig. 3a (Student’s t-test, FDR < 0.01). Although Bland-Altman plots 
showed a general bias for lower methylation levels measured by pyrosequencing (Supplementary Figure S3), the 
correlation in measurements between the two methodologies was highly concordant for all 4 sites (Spearman’s 
correlation rs > 0.7, FDR < 0.001) (Supplementary Figure S3).
ǦơǤ To fur-
ther test the robustness of our EWAS findings, we analysed the previously mentioned 4 sites in T-cells of an 
Figure 1. Differential sites and regions identified in the 450 K array analyses. (a) Volcano plot depicting 
differences in DNAm levels between controls and patient (T1) for each probe in the corrected 450 K dataset 
(indicated on X axis) against FDR (indicated on Y axis, on –log10 scale). Dashed horizontal line denotes FDR 
threshold of 0.1 while dashed vertical lines denote DNAm difference thresholds of −0.05 and 0.05, respectively. 
(b) Differential DNAm detected by DMRcate in the promoter region of the SRPK3 gene (chrX:153, 046, 
386–153, 046, 482). (c) Volcano plot depicting differences in DNAm levels between patients (T1) and patients 
(T2) as described in panel (a). (d) DNAm levels of seven sites which show reversion of DNAm post-treatment. 
***Indicate an FDR < 0.001.
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independent replication cohort by pyrosequencing. The two top-ranking hits, cg07280807 in an intergenic region 
and cg18752527 in HECW2, were differentially methylated in the replication cohort (FDR < 0.05, one-sided 
t-test) (Fig. 3b). However, the two sites within the SRPK3 promoter region (cg16529483 and cg24496423) did not 
replicate in this cohort, likely due to insufficient power with the low sample size in this cohort, but showed a trend 
in the same direction as in the discovery cohort.
ơǤ To identify sites that are not only differen-
tially methylated in T-cells, but also in whole blood DNA, we sought to reproduce our most robust EWAS findings 
from T-cells in whole blood DNA samples of both our discovery and replication cohorts. Therefore, we analysed 
DNAm of the 4 previously mentioned sites in whole blood samples by pyrosequencing. We observed differen-
tial methylation of cg18752527 in the intragenic region of HECW2 between controls and patients (T1) in both 
cohorts (FDR < 0.05, Student’s t-test) (Fig. 3c). Furthermore, similar to the findings from T-cells, the two sites 
within the SRPK3 promoter region (cg16529483 and cg24496423) were differentially methylated in whole blood 
samples of the discovery cohort (Fig. 3d), but not of the replication cohort. We found that differential DNAm of 
cg07280807 did not replicate in whole blood of either cohort. Using a previous 450 K dataset of purified blood cell 
types45, we confirmed that the DNAm status of cg18752527 in HECW2 was highly associated with T-cells, along 
with NK cells, suggesting that the DNAm differences we measured in whole blood were driven, in part, by T-cells 
(P = 7.6E-15, ANOVA) (Supplementary Figure S4). The DNAm statuses of the two sites in the SRPK3 promoter 
were not associated with any specific cell type (Supplementary Figure S4).
Discussion
By analysing genome-wide DNAm profiles of purified CD3+ T-cells using the Illumina 450 K array, we found 
59 CpG sites to be differentially methylated in a group of 24 alcohol dependent patients compared to 23 closely 
matched healthy controls. These site-specific hits showed considerable overlap to detected DMRs, suggesting 
that the results were not contingent on the analytical approach used. Furthermore, we discovered 48 sites that 
were differentially methylated between AD patients at the time of hospital admission (T1) and after 3 weeks 
(T2) of participation in an alcohol treatment program and showed a reversion of some of the AD-associated 
sites post-treatment. In addition, we were able to validate four of the top-ranking AD-associated hits by pyrose-
quencing, and replicate two of them in an independent cohort. Finally, we found the top-ranked hits in HECW2 
(cg18752527) and SRPK3 (cg16529483 and cg24496423) to be differentially methylated in whole blood, signifying 
the potential relevance of these associations in other blood cell types. To our knowledge, this is the first study to 
assess and replicate alcohol-associated differential DNAm in purified T-cells and to assess DNAm variation that 
may be related to early recovery from AD in closely matched human population cohorts.
Probe ID Gene Region
Average beta 
Controls
Average beta 
Patients (T1) Δ-beta P-Value BH-adjusted P-value
a) Differentially methylated sites between Controls and Patients (T1)
cg18752527* HECW2 intragenic 0.342 0.276 0.066 4.30E-07 0.0213
cg08109624 intergenic 0.760 0.817 −0.057 8.15E-07 0.0234
cg10168086 intergenic 0.535 0.484 0.051 1.24E-06 0.0256
cg07280807* intergenic 0.755 0.822 −0.068 2.44E-06 0.0366
cg12173150 intergenic 0.321 0.385 −0.064 3.02E-06 0.0370
cg01059398 TNFSF10 intragenic 0.261 0.209 0.052 1.07E-05 0.0627
cg17940902 HLA-DMA promoter 0.399 0.450 −0.051 1.19E-05 0.0640
cg22778903 MX2 intragenic 0.304 0.355 −0.051 1.34E-05 0.0666
cg14612335 SKIL promoter 0.423 0.368 0.055 1.38E-05 0.0666
cg11580026 intergenic 0.600 0.549 0.051 1.51E-05 0.0691
Probe ID Gene Region Average beta Patients (T1)
Average beta 
Patients (T2) Δ-beta P-Value BH-adjusted P-value
b) Differentially methylated sites between Patients (T1) and Patients (T2)
cg15500907 LAMA4 intragenic 0.485 0.542 −0.056 1.01E-06 0.0323
cg05266321 CCR2 intragenic 0.545 0.606 −0.061 4.63E-06 0.0487
cg13279700 C6orf10 intragenic 0.481 0.544 −0.063 1.76E-05 0.0561
cg14054990 KRTAP19-5 promoter 0.431 0.482 −0.052 1.84E-05 0.0565
cg21049302 intergenic 0.466 0.522 −0.056 1.98E-05 0.0565
cg17022548 NRG2 intragenic 0.204 0.258 −0.054 1.99E-05 0.0565
cg22472360 TRIO intragenic 0.514 0.569 −0.055 2.09E-05 0.0569
cg07920414 RIMS3 intragenic 0.438 0.493 −0.055 2.18E-05 0.0572
cg04088338 intergenic 0.378 0.429 −0.051 2.54E-05 0.0590
cg12240358 HOMER2 intragenic 0.462 0.519 −0.057 2.68E-05 0.0590
Table 2. Top 10 differentially methylated sites a) between controls and patients (T1) and b) between patients 
(T1) and patients (T2). Probe IDs marked with an asterisk were validated by pyrosequencing. Abbreviations: 
Average beta, mean methylation values (%); Benjamini-Hochberg (BH) adjusted P-value.
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EWAS pose an excellent hypothesis-free opportunity to identify as yet undiscovered disease-associated 
genes. Our EWAS findings of AD-associated differential DNAm revealed both site-specific and regional dif-
ferences between patients before treatment and matched controls in a clinically relevant cell type. The observed 
bi-directional patterns of changes are consistent with previous evidence of AD-associated differential DNAm26, 
29, 31, 33, 35. However, our findings derived from T-cells did not overlap with previously reported associations of AD 
with DNAm26, 29, 31, 33, 35. This can at least in part be explained by the use of heterogeneous biological material (i.e. 
whole blood, PBMCs), differences in the cohorts used or in the strategies applied to match patients and controls 
as well as by varying methodologies for DNAm measurement, with reduced or discordant coverage of CpG sites 
in previous studies26, 31, 33, 35 compared to the present study. However, our top-ranking hits in HECW2 and SRPK3 
might contribute to reveal mechanisms that may play a role in AD. HECW2 is a HECT-type E3 ubiquitin ligase 
involved in the cellular stress response46, 47. This finding is in line with previous evidence for the role of epigenetic 
regulation of cellular stress response genes in AD, such as GDAP1, which was identified in a previous EWAS31 
and subsequently replicated in whole blood samples derived from an independent cohort25. However, GDAP1 
did not come up in this present analysis using DNA isolated from purified T-cells. Presumably, the previously 
described differential methylation of GDAP1 in whole blood is driven by another cell type other than T-cells. 
SRPK3 encodes a serine/arginine protein kinase and is essential for the development of the skeletal muscle48. It 
was shown that the drosophila homolog SRPK79D plays an important role in the function of synapses49. Although 
an association between SRPK3 and the nervous system in humans has not been described so far, the high homol-
ogy between SRPK79D and SRPK3 (65%) makes an as yet uncharacterized role in the nervous system possible.
In addition to the assessment of AD-associated differential DNAm in T-cells prior to alcohol treatment, we 
also examined treatment-related site-specific alterations in DNAm by comparing DNAm profiles in T-cells of 
patients before (T1) and after a 3-week alcohol treatment (T2). Our findings include numerous sites in which 
DNAm in patients (T2) reverts back to levels comparable to those observed in controls. More specifically, we 
showed post-treatment DNAm reversion (at 7 sites) or partial reversion (at 32 sites) back to control levels. 
These findings confirm the results of a previous pilot study, which also showed reversion of DNAm after a short 
term alcohol treatment program31. Other epigenetic studies in human populations investigating the effect of 
short-term treatments, including exercise or dietary interventions, on DNAm of relevant tissues have identified 
similar numbers of site-specific DNAm changes with a comparable magnitude of effect sizes to our findings50, 51.
Based on our assessment of mean global DNAm, measured as averaged methylation across all interrogated 
CpGs, we found that global DNAm levels were significantly lower in patients prior to the alcohol treatment com-
pared to controls. Following alcohol treatment, the mean global DNAm of patients no longer differed significantly 
from controls. These results are in accordance with the unidirectionality of our treatment-related hits, with all 
significant sites exhibiting increased DNAm after treatment, and with our site-specific findings that numerous 
AD-associated CpGs exhibited post-treatment reversion to levels comparable to controls. The reduction in mean 
global DNAm observed in AD patients is supported by previous studies, which also demonstrated decreased 
methylation29, 36. It has been hypothesized that such alcohol-associated decreases in global DNAm are attributed 
to the lack of methionine adenosyl transferase regulation in AD patients14, 52. However, in contrast, earlier studies 
have postulated that due to the higher homocysteine levels in AD patients, global DNAm patterns should be 
elevated53, although such associations have not been confirmed54. The lack of consensus in regard to alterations 
in alcohol-related global DNAm measures highlights the need for further investigation into the biological mech-
anisms underlying global DNAm patterns in AD patients.
Figure 2. Mean global DNAm differences and naïve T-cell subtype differences between groups. (a) Patients 
(T1) showed significantly decreased mean global DNAm levels compared to controls (P = 0.048, Mann-
Whitney U test). Differences between controls vs. patients (T2) and patients (T1) vs. patients (T2) were not 
significant. (b) Abundance levels of naïve CD8+ and CD4+ T-cells were predicted using an advanced blood 
DNA methylation age prediction tool. Both naïve T-cell subtypes significantly increased post-treatment in 
patients (**Indicates an FDR < 0.01, Wilcoxon signed-rank test) but were not significantly different between 
controls and patients at either time point.
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Using bioinformatic predictions from our T-cell DNAm profiles, we observed a significant increase in naive 
CD4+ and CD8+ T-cell subsets post-treatment, which is consistent with evidence of decreased frequencies of 
these naïve T-cell subtypes due to chronic AD37, 39 and a resultant restoration of peripheral T-cell numbers fol-
lowing short-term alcohol abstinence38. These findings, along with known effects of alcohol dependence on T-cell 
homeostasis, proliferation and activation39, 55, highlight the importance of understanding alcohol-related effects 
on T-cell-specific biology, particularly in the context of AD pathophysiology and treatment, of which our study 
serves as the first to profile such AD-associated changes on the T-cell epigenome.
In order to verify that our results are robust and largely reflective of potential biological variation as opposed 
to technical variation, we took a number of precautions in our analyses, including I) constraining our hits to 
sites with DNAm differences greater than 5% between groups in order to increase the likelihood of biological 
relevance, II) confirming 450 K measures by pyrosequencing and III) validating top-ranked hits by pyrosequenc-
ing in an independent replication cohort. Although we observed a general bias between the two methodologies, 
in which the pyrosequencing measures were lower than 450 K values, there was high concordance of measures 
between the two methods and we were still able to detect significant differences in DNAm between groups, signi-
fying the strength of our results. Moreover, we were able to confirm three top-ranking hits from purified T-cells 
in whole blood, further strengthening the robustness of our findings and highlighting their potential importance 
in AD.
It is important to note that our study had a few inherent limitations. Firstly, using bioinformatic cell type 
predictions, we detected notable levels (up to 32%) of cellular contamination in our bead-purified T-cell samples. 
This is consistent with previous work which confirmed the presence of cellular heterogeneity in samples even 
after purification using cell surface markers56. We removed cell heterogeneity using a regression-based method, 
thereby ensuring inter-individual differences in cell composition were normalized in our dataset prior to DNAm 
analyses. Secondly, our analyses were limited by a rather small sample size. To work around this limitation, we 
Figure 3. Validation and replication of top-ranking hits by pyrosequencing. (a) Boxplots showing differences in 
DNAm levels of discovery cohort T-cell samples as measured by pyrosequencing (FDR < 0.01, Student’s t-test). 
(b) Two top-ranked hits (cg07280807 and cg18752527) were verified as being differentially methylated in T-cell 
samples of the replication cohort (FDR < 0.05, one-sided t-test). (c) Verification of differential methylation of 
cg18752527 (HECW2) in the discovery (left) and the replication cohort (right) in DNA derived from whole 
blood (FDR < 0.05, two-sided t-test). (d) Verification of cg16529483 and cg24496423 (SRPK3) differential 
methylation in the discovery cohort in DNA derived from whole blood (FDR < 0.01, two-sided t-test).
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utilized a relaxed FDR threshold in the differential methylation modelling to capture more potentially biologically 
relevant sites and focused on validating and replicating our top-ranked hits to ensure these results were robust. 
Although we were able to validate the hits within the SRPK3 promoter by pyrosequencing in T-cell and whole 
blood samples of the discovery cohort, we could not replicate the differential DNAm of SRPK3 in our second 
cohort, unlike our findings for HECW2. This probably results from insufficient statistical power due to the low 
sample size of the replication cohort. We acknowledge that the small samples size analysed in our study could also 
hinder successful validation of our results in future studies. The phenomenon of non-replication could also be 
observed in previous transcriptome-wide studies in human populations of AD patients and control individuals, 
where the overlap between the individual studies was fairly small57, 58. However, by technically validating and 
replicating our results in a second cohort, we made an attempt to reduce the risk of false-positive findings to a 
minimum. Despite these efforts, our results should be verified in a larger cohort spanning different populations 
to confirm the associations for HECW2 and SRPK3. So far, neither HECW2 nor SRPK3 were among top-ranked 
hits in transcriptome-wide studies. Therefore, functional data is required to investigate the interplay of DNAm, 
transcription and functioning of these genes related to AD. Thirdly, we cannot rule out that the DNAm differences 
between the patients before (T1) and after treatment (T2) may be due to stochastic temporal DNAm variation, 
although previous work in blood has revealed minimal evidence of temporal variation in the majority of 450 K 
probes across a 9 month period59. In addition, differences in DNAm could also be due to direct influences of 
acute ethanol intoxication, which has been shown to have an effect on transcriptome regulation57, 58. We tried to 
circumvent this limitation by only including subjects who had their last drink in a narrow time frame of 1.2 ± 0.6 
days. Additionally, the 20 CpG sites which did not change from pre- to post-treatment could potentially be differ-
entially methylated due to chronic alcohol exposure and not due to early withdrawal. To clarify this issue, future 
longitudinal studies are warranted. Finally, we cannot disregard the potential influence of genetic variation on 
our differentially methylated CpG sites. However, we attempted to reduce genetic heterogeneity in our cohort by 
using only Caucasian participants.
In conclusion, we report that AD is associated with lower mean global DNAm and with differential DNAm 
of specific sites in CD3+ T-cells. Additionally, we were able to identify changes in DNAm related to alcohol treat-
ment in patients. These changes include the reversion of AD-associated DNAm alterations at certain sites to levels 
comparable to controls. Validation of our top-ranking associations by pyrosequencing and replication of our 
top-ranked hits in a second independent cohort strongly supports the robustness of our results. Finally, we show 
that the differential methylation of HECW2 and SRPK3 is not only present in T-cells, but also in whole blood, 
indicating that HECW2 and SRPK3 are likely robust findings which should be followed up in future studies.
Methods
Study cohorts. The discovery study cohort was comprised of 24 male AD patients (mean age 47.5 ± 10.1 
years) participating in a 3-week in-patient alcohol treatment program at the Clinic for Psychiatry and 
Psychotherapy in Tuebingen, Germany. AD was diagnosed according to the fourth edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV). Twenty-three population based, sex- and age-matched healthy 
controls (mean age 46.9 ± 10.3 years) were recruited from Tuebingen and the surrounding area. The replication 
study cohort was comprised of 13 male AD patients (mean age 50.9 ± 9.1 years) and 12 matched healthy controls 
(mean age 45.3 ± 16.2 years). In addition, the smoking behaviour (measured as cigarettes per day) of both groups 
was matched. Subjects with a dependence other than nicotine and patients with any psychiatric disorder neces-
sitating psychotropic medication were excluded from the study. All subjects were of Caucasian origin and gave 
written informed consent after recovering from alcohol intoxication (patients) or prior to participation in the 
study (controls), which was approved by the ethics committee of the University of Tuebingen and was conducted 
in accordance with the Declaration of Helsinki.
After recovery from alcohol intoxication and at the time of study inclusion, respectively (time point 1, T1), 
patients and controls answered a self-administered phenotypic and demographic questionnaire, the Alcohol Use 
Disorder Identification Test (AUDIT)60, assessing alcohol consumption, and the Symptom Checklist-90-R (SCL-
90-R) questionnaire61, assessing the global distress level (GSI). Patients also answered the obsessive compulsive 
drinking scale (OCDS-G) questionnaire, reflecting obsession and compulsivity related to craving and drinking 
behavior62. OCDS-G and SCL-90-R were reassessed after three weeks ( ± 2 days) of participation in the alcohol 
treatment program (time point 2, T2). Controls with AUDIT scores >15 were excluded, as a higher value is sug-
gestive for problematic alcohol intake.
At T1 and T2, peripheral venous blood was drawn from patients in Ethylenediaminetetraacetic (EDTA) and 
Mononuclear Cell Preparation tubes (CPT, both BD, Franklin Lakes, NJ, USA). EDTA and CPT blood samples 
from the controls were drawn at study inclusion. Samples for whole blood DNA extraction were kept at −80 °C 
until further usage.
͹+ǦƤǤ Immediately after blood draw, PBMCs were first separated 
via centrifugation of the CPT tubes for 20 min at 1650 × g. CD3+ T-cells were then purified from PBMCs follow-
ing the positive isolation protocol using Dynabeads CD3 (Invitrogen, Carlsbad, CA, USA). The cells were subse-
quently lysed and DNA was prepared using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to 
standard protocol.
Ƥͺ ͻͶǤ T-cell DNA (750 ng) was bisulfite 
converted using the Zymo Research EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA). DNA yield 
and purity was assessed using a Nanodrop ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA). Samples 
were subsequently randomized and 160 ng of bisulfite-converted DNA was applied to the Illumina Infinium 
73
www.nature.com/scientificreports/
9SCIENTIFIC REPORTSȁͽǣ6605ȁǣͷͶǤͷͶ͹;ȀͺͷͻͿ;ǦͶͷͽǦͶͼ;ͺͽǦ
HumanMethylation450K (450 K) Beadchip array, as per manufacturer’s protocols (Illumina, San Diego, CA, 
USA).
ǡơ
analyses. Raw data from the 450 K array was subjected to quality control, normalization and batch correc-
tion. Subsequently, remaining contamination of the purified T-cells was bioinformatically removed from the 
dataset. After subsetting the corrected data in 3 groups (controls vs. patients (T1); patients (T1) vs. patients (T2); 
controls vs. patients (T2)), site-specific differential DNAm was assessed by linear regression modelling while 
differentially methylated region (DMRs) were identified using the DMRcate package as described earlier63. A 
detailed description of all analyses can be found in the supplementary methods. The 450 K data has been made 
publicly available on the Gene Expression Omnibus database (GSE98876).
Pyrosequencing-based validation and replication in T-cells. 500 ng T-cell DNA was 
bisulfite-converted using the Epitect Fast Bisulfite Conversion Kit (Qiagen) as described ear-
lier25. For amplification of the region of interest, PCR was conducted using the PyroMark PCR 
Kit (Qiagen) with the following primers: forward (fwd): 5′-GTTATGGTTGGGTTTTTGGG-3′, 
r e v e r s e  ( re v ) :  5 ′ - B i o - C C TAT C T C C T C A A AC A A A A AC TA A A A A- 3 ′ ,  s e qu e n c i n g  ( s e q ) : 
5′-AGTTAGGGATTATAGTGTAGTTG-3′ (cg07280807); fwd: 5′-GTGTTTGTGGGAATGTTTTTTATA-3′, 
rev: 5′-Bio- CACACTACACTTTCATTTTCTATCAA-3′, seq: 5′- TTTTTAGATATATAAATTTTTTTTTT-3′ 
( c g 1 8 7 5 2 5 2 7 )  a n d  f w d / s e q :  5 ′ - G T TAT T TATA A A G G A G G G T G A G AT TA - 3 ′ ,  r e v : 
5′-Bio-AACCACTACTCCTATAAAACCCCAC-3′ (cg16529483/cg24496423). A detailed list of PCR primers 
and programs is provided in Supplementary Table S4. Specificity of the PCR was verified by agarose gel electro-
phoresis including a negative control. Pyrosequencing was conducted on a PyroMark Q24 according to standard 
protocol using PyroMark Gold Reagents (both Qiagen). Each sample was measured in triplicates; an intra-sample 
deviation of ≥3% led to the exclusion of the deviating measurement. For each site, measurements of DNA with 
known methylation levels of 0%, 25%, 50%, 75% and 100% were obtained (Epitect Control DNA, Qiagen). 
Correlations between the 450 K dataset and pyrosequencing were tested using the Spearman’s correlation test.
Pyrosequencing-based validation and replication in whole blood. DNA was prepared from EDTA 
tubes using QIAamp DNA Blood Maxi Kit (Qiagen) according to manufacturer’s protocol. Afterwards, bisulfite 
conversion and pyrosequencing was carried out as described above.
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 Supplementary methods 
DNA methylation array data quality control and normalization: Quality control, 
processing and differential DNAm analysis of 450K array data was performed as 
previously described.1,2 Briefly, raw intensity values from the arrays were imported 
into Illumina GenomeStudio V2011.1 software and subjected to initial quality control 
checks for array staining, extension and bisulfite conversion followed by color 
correction and background adjustment using control probes contained on the 450K 
array. Subsequent processing and analysis were performed in R Version 3.2.1 
(http://www.r-project.org). Profiles from 65 probes targeting single nucleotide 
polymorphisms (SNPs) were used to ensure T1 and T2 samples were indeed 
matched from the same individual. The 65 SNP probes were also filtered out of the 
dataset. Additional probe filtering was performed in which poor performing probes 
including those with detection P-values greater than 0.01, probes with missing beta 
values, and probes for which less than three beads contributed to the signal in any 
sample were eliminated (a total of 13 903). Recent re-annotation of the Illumina 450K 
array3 was used to filter 19 343 probes that are known to be polymorphic at the target 
CpG. Probes which have nonspecific in silico binding to the sex chromosomes were 
assessed in a post-hoc analysis following differential DNAm analysis to ensure they 
did not overlap with identified hits.3 Together, quality control checks eliminated 33 
311 probes, leaving a total of 452 266 probes for further analysis. Following quality 
control processing, quantile normalization was conducted using the lumi R package4 
after assessment using the quantro package indicated that quantile normalization 
was appropriate for this dataset.5 Differences between Type I and Type II probes on 
the 450K array were normalized using Subset-quantile Within Array Normalization 
(SWAN).6 ComBat7 was then used to remove chip and row effects, while protecting 
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 sample group. Removal of technical variation was assessed by principal component 
analysis (PCA). 
Blood cell type deconvolution: To test for potential contamination of bead-purified 
CD3+ T-cell samples by other blood cell types, a well-established algorithm was used 
to bioinformatically estimate cell type composition based on underlying reference 
DNAm profiles.8,9 In addition, the 450K data was subjected to advanced DNA 
methylation age analysis in blood using a publicly available DNA methylation age 
predictor tool in order to obtain predicted abundance measures of additional blood 
cell types including plasma blasts, CD8+CD28-CD45RA- (memory and effector) T-
cells, naïve CD8+ T-cells and naïve CD4+ T-cells.10 Upon detection of potential non-
T-cell contamination in a fraction of samples, we removed this cell-type composition 
variation by regressing probewise DNAm on estimated cell type proportions, as 
previously described.11 The residuals of each regression model were applied to the 
mean value of each data series to obtain the ‘corrected’ DNAm data. PCA was 
subsequently used to check that the presence of the cell type proportions in DNAm 
variation was minimal in the corrected dataset. PCA was additionally used to check 
for correlation of other known meta-variables (i.e. sample group, age, daily smoking) 
with the underlying DNAm patterns of the uncorrected and corrected 450K datasets, 
respectively. Note that for all PCA analyses, the top-ranking PC (denoted as PC0) 
was negated as it is not informative of inter-individual variance in the DNAm data.12  
Differential methylation analyses of 450K dataset: The cell-type corrected 450K 
dataset was subsetted into controls versus patients (T1), patients (T1) versus 
patients (T2) and controls versus patients (T2) sample sets, respectively, prior to 
differential DNAm analysis. In the genome-wide analyses, differentially methylated 
probes were identified using the R limma package’s moderated t-statistics with 
empirical Bayesian variance estimation.13 Specifically, in the comparison of controls 
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versus patients (T1), a linear model was fit for each probe’s DNAm measures with 
sample group as the main effect, adjusted for age and smoking levels. In the 
comparison of patients (T1) and patients (T2) samples, differentially methylated 
probes were identified using paired testing in linear regression analysis. For both of 
these comparisons, differentially methylated regions (DMRs) were detected using 
DMRcate package which uses the moderated t-statistics generated in their respective 
limma analyses.14 In the comparison of controls versus patients (T2), we sought to 
assess which differentially methylated sites between controls and patients (T1) 
exhibited reversion in the patient (T2) samples such that their DNAm levels were 
comparable to controls. To address this, we specifically tested the 59 hits identified 
between controls versus patients (T1) (FDR < 0.1 and DNAm difference > 5%) by 
fitting individual linear models for each of the 59 probes. For all tests, the resulting P-
values were adjusted using the Benjamini-Hochberg False Discovery Rate (FDR) 
method.15 All statistical analyses were performed on transformed M-values.16 
Questionnaire evaluation: The AUDIT score is the sum of all 10 items of the 
questionnaire. The GSI score represents the sum of all the subscales of the SCL-90-
R divided by the number of answered items (usually 90). For the OCDS score, the 
higher value of four item pairs (Items 1 and 2, 7 and 8, 9 and 10, and 12 and 13) was 
added up with the remaining items, leading to a potential range of 0 to 40. Up to one 
missing item was allowed and replaced by adding the mean of all other items. 
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Supplementary Figure S1. Estimations of blood cell proportions in samples based on 
underlying reference DNAm profiles. Estimates were predicted using the Houseman blood 
cell deconvolution algorithm. There was no statistically significant association between 
predicted proportions of any cell type and sample group (Mann-Whitney U test for 
comparison of controls and patients (T1) or controls and patients (T2); Wilcoxon signed-rank 
test for comparison of matched patients (T1) and patients (T2) samples). 
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Supplementary Figure S2. Principal component analyses before and after regression-
based adjustment of the 450K data. PCA showing the correlation of known phenotypic and 
technical variables to the top 10 principal components, each representing an incremental 
proportion of the variance in the methylation data. a) Top 10 PCs in unadjusted 450K dataset 
(representing 60% of the DNAm variance) and b) top 10 PCs in the adjusted 450K dataset 
(representing 45% of the DNAm variance). 
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Supplementary Table S1. Differentially methylated sites between Controls and Patients (T1) 
# Probe ID Gene Region Average 
beta 
Controls 
Average 
beta 
Patients (T1) 
Δ-beta P-Value BH-
adjusted 
P-Value
1 cg18752527 HECW2 intragenic 0.342 0.276 0.066 4.30E-07 0.0213
2 cg08109624 None intergenic 0.760 0.817 -0.057 8.15E-07 0.0234 
3 cg10168086 None intergenic 0.535 0.484 0.051 1.24E-06 0.0256 
4 cg07280807 None intergenic 0.755 0.822 -0.068 2.44E-06 0.0366 
5 cg12173150 None intergenic 0.321 0.385 -0.064 3.02E-06 0.0370 
6 cg01059398 TNFSF10 intragenic 0.261 0.209 0.052 1.07E-05 0.0627 
7 cg17940902 HLA-DMA promoter 0.399 0.450 -0.051 1.19E-05 0.0640 
8 cg22778903 MX2 intragenic 0.304 0.355 -0.051 1.34E-05 0.0666 
9 cg14612335 SKIL promoter 0.423 0.368 0.055 1.38E-05 0.0666 
10 cg11580026 None intergenic 0.600 0.549 0.051 1.51E-05 0.0691 
11 cg12284098 MYOM2 intragenic 0.534 0.477 0.056 1.54E-05 0.0691 
12 cg26091609 CTLA4 intragenic 0.578 0.518 0.060 1.59E-05 0.0691 
13 cg09768654 SRPK3 promoter 0.374 0.466 -0.092 1.65E-05 0.0691 
14 cg06851207 PNMAL1 promoter 0.528 0.617 -0.089 1.84E-05 0.0691 
15 cg14702960 None intergenic 0.742 0.689 0.052 1.92E-05 0.0691 
16 cg00449728 MAPRE2 intragenic 0.750 0.693 0.057 2.98E-05 0.0702 
17 cg22851561 ELMSAN1 intragenic 0.432 0.380 0.052 3.00E-05 0.0702 
18 cg02536838 ANGPT1 promoter 0.605 0.530 0.075 3.14E-05 0.0702 
19 cg15841511 None intergenic 0.729 0.788 -0.059 3.42E-05 0.0706 
20 cg24392939 CRYBG3 intragenic 0.562 0.510 0.052 3.62E-05 0.0725 
21 cg12761472 CEP85L promoter 0.621 0.566 0.055 4.13E-05 0.0754 
22 cg02652579 SYNGAP1 promoter 0.623 0.563 0.059 4.17E-05 0.0758 
23 cg22865905 SNORA69 three_plus 0.794 0.743 0.051 4.26E-05 0.0764 
24 cg27201673 PNMAL1 promoter 0.213 0.263 -0.050 5.41E-05 0.0778 
25 cg04936619 C17orf75 intragenic 0.314 0.245 0.069 5.88E-05 0.0778 
26 cg11121969 PCBP3 promoter 0.691 0.627 0.064 6.26E-05 0.0778 
27 cg00246693 ARHGAP42 Promoter 0.340 0.393 -0.053 7.10E-05 0.0778 
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# Probe ID Gene Region Average 
beta 
Controls 
Average 
beta 
Patients (T1) 
Δ-beta P-Value BH-
adjusted 
P-Value
28 cg10399005 None intergenic 0.776 0.833 -0.057 7.11E-05 0.0778
29 cg16529483 SRPK3 promoter 0.252 0.357 -0.105 7.18E-05 0.0780 
30 cg01220513 SH3KBP1 intragenic 0.506 0.454 0.051 8.08E-05 0.0791 
31 cg26926002 None intergenic 0.719 0.777 -0.058 8.10E-05 0.0791 
32 cg14544087 MIR155HG intragenic 0.290 0.227 0.063 8.64E-05 0.0791 
33 cg20893919 TRPC3 intragenic 0.703 0.754 -0.051 9.23E-05 0.0801 
34 cg18682028 FYCO1 intragenic 0.394 0.338 0.056 9.24E-05 0.0801 
35 cg04362790 None intergenic 0.697 0.644 0.052 9.32E-05 0.0801 
36 cg09060654 LIPA intragenic 0.578 0.656 -0.079 9.51E-05 0.0801 
37 cg02451774 NBPF8 intragenic 0.431 0.483 -0.053 9.98E-05 0.0806 
38 cg18723276 USP29 promoter 0.723 0.774 -0.051 0.0001 0.0819 
39 cg13180722 None intergenic 0.338 0.401 -0.062 0.0001 0.0830 
40 cg12230162 SRPK3 promoter 0.357 0.463 -0.105 0.0001 0.0835 
41 cg18890544 None intergenic 0.846 0.905 -0.059 0.0001 0.0839 
42 cg24496423 SRPK3 promoter 0.309 0.393 -0.084 0.0001 0.0854 
43 cg02661764 None intergenic 0.419 0.360 0.059 0.0001 0.0867 
44 cg01400671 None intergenic 0.409 0.345 0.064 0.0001 0.0874 
45 cg13609457 None intergenic 0.577 0.521 0.056 0.0002 0.0897 
46 cg25880958 None intergenic 0.591 0.645 -0.054 0.0002 0.0898 
47 cg18376497 INPP4B intragenic 0.286 0.223 0.064 0.0002 0.0919 
48 cg13784312 RAPGEF1 intragenic 0.187 0.136 0.051 0.0002 0.0928 
49 cg07135405 MIR1914 three_plus 0.540 0.394 0.146 0.0002 0.0928 
50 cg20475486 None intergenic 0.702 0.759 -0.058 0.0002 0.0936 
51 cg11858450 CCDC105 intragenic 0.709 0.762 -0.053 0.0002 0.0940 
52 cg05927817 None intergenic 0.726 0.787 -0.061 0.0002 0.0940 
53 cg00306893 None intergenic 0.737 0.675 0.062 0.0002 0.0940 
54 cg10365886 TNXB intragenic 0.566 0.672 -0.105 0.0002 0.0947 
55 cg27503950 None intergenic 0.633 0.696 -0.063 0.0002 0.0952 
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# Probe ID Gene Region 
Average 
beta 
Controls 
Average 
beta 
Patients (T1) 
Δ-beta P-Value
BH-
adjusted 
P-Value
56 cg01089001 GALNT18 intragenic 0.317 0.382 -0.065 0.0002 0.0953
57 cg12564698 GAL three_plus 0.312 0.261 0.051 0.0002 0.0953 
58 cg16197188 NRG3 intragenic 0.723 0.672 0.051 0.0003 0.0995 
59 cg04088338 None intergenic 0.430 0.378 0.052 0.0003 0.0999 
Abbreviations: Average beta, mean methylation values (%); Benjamini-Hochberg (BH) adjusted P-value. 
85
S
u
p
p
le
m
e
n
ta
ry
 T
a
b
le
 S
2
. 
T
o
p
 l
is
te
d
 h
it
s
 d
e
te
c
te
d
 b
y
 b
o
th
 s
it
e
-s
p
e
c
if
ic
 a
n
d
 D
M
R
c
a
te
 a
n
a
ly
s
is
. 
P
ro
b
e
 I
D
 
G
e
n
e
 
D
M
R
 
P
o
s
it
io
n
 
A
v
e
ra
g
e
 b
e
ta
 
C
o
n
tr
o
ls
 
A
v
e
ra
g
e
 b
e
ta
 
P
a
ti
e
n
ts
 (
T
1
) 
Δ
-b
e
ta
 
P
-V
a
lu
e
F
D
R
 
c
g
1
6
5
2
9
4
8
3
 
S
R
P
K
3
 
c
h
rX
:1
5
3
0
4
6
1
7
5
-
1
5
3
0
4
7
7
0
7
 
1
5
3
0
4
6
4
5
1
 
0
.2
5
2
 
0
.3
5
7
 
-0
.1
0
5
3
.5
2
E
-2
3
 
5
.9
0
E
-1
9
 
c
g
2
4
4
9
6
4
2
3
 
S
R
P
K
3
 
c
h
rX
:1
5
3
0
4
6
1
7
5
-
1
5
3
0
4
7
7
0
7
 
1
5
3
0
4
6
4
8
0
 
0
.3
0
9
 
0
.3
9
3
 
-0
.0
8
4
2
.8
4
E
-2
3
 
4
.9
4
E
-1
9
 
c
g
1
2
2
3
0
1
6
2
 
S
R
P
K
3
 
c
h
rX
:1
5
3
0
4
6
1
7
5
-
1
5
3
0
4
7
7
0
7
 
1
5
3
0
4
6
4
8
2
 
0
.3
5
7
 
0
.4
6
3
 
-0
.1
0
5
2
.8
0
E
-2
3
 
4
.9
4
E
-1
9
 
c
g
0
9
7
6
8
6
5
4
 
S
R
P
K
3
 
c
h
rX
:1
5
3
0
4
6
1
7
5
-
1
5
3
0
4
7
7
0
7
 
1
5
3
0
4
6
3
8
6
 
0
.3
7
4
 
0
.4
6
6
 
-0
.0
9
2
6
.7
2
E
-2
3
 
1
.0
1
E
-1
8
 
c
g
1
8
8
9
0
5
4
4
 
c
h
r1
:2
4
2
2
2
0
3
0
1
-
2
4
2
2
2
0
9
2
5
 
2
4
2
2
2
0
5
3
8
 
0
.8
4
6
 
0
.9
0
5
 
-0
.0
5
9
1
.7
5
E
-1
8
 
8
.8
8
E
-1
5
 
c
g
0
8
1
0
9
6
2
4
 
c
h
r1
:2
4
2
2
2
0
3
0
1
-
2
4
2
2
2
0
9
2
5
 
2
4
2
2
2
0
9
2
5
 
0
.7
6
0
 
0
.8
1
7
 
-0
.0
5
7
1
.6
9
E
-1
9
 
1
.0
2
E
-1
5
 
c
g
2
7
5
0
3
9
5
0
 
c
h
r6
:1
6
0
0
2
3
5
8
1
-
1
6
0
0
2
4
1
4
4
 
1
6
0
0
2
4
0
0
2
 
0
.6
3
3
 
0
.6
9
6
 
-0
.0
6
3
2
.9
2
E
-1
5
 
6
.5
7
E
-1
2
 
c
g
0
9
0
6
0
6
5
4
 
L
IP
A
 
c
h
r1
0
:9
0
9
8
5
0
5
5
-
9
0
9
8
5
0
6
2
 
9
0
9
8
5
0
6
2
 
0
.5
7
8
 
0
.6
5
6
 
-0
.0
7
9
1
.9
6
E
-0
7
 
4
.5
3
E
-0
5
 
A
b
b
re
v
ia
ti
o
n
s
: 
A
v
e
ra
g
e
 b
e
ta
, 
m
e
a
n
 m
e
th
y
la
ti
o
n
 v
a
lu
e
s
 (
%
);
 F
D
R
, 
B
e
n
ja
m
in
i-
H
o
c
h
b
e
rg
 F
a
ls
e
 D
is
c
o
v
e
ry
 R
a
te
; 
D
M
R
, 
d
if
fe
re
n
ti
a
lly
 
m
e
th
y
la
te
d
 r
e
g
io
n
. 
86
Supplementary Table S3. Differentially methylated sites between Patients (T1) and Patients (T2) 
# Probe ID Gene Region Average 
beta 
Patients (T1) 
Average 
beta 
Patients (T2) 
Δ-beta P-Value BH-
adjusted 
P-Value
1 cg15500907 LAMA4 intragenic 0.485 0.542 -0.056 1.01E-06 0.0323
2 cg05266321 CCR2 intragenic 0.545 0.606 -0.061 4.63E-06 0.0487 
3 cg13279700 C6orf10 intragenic 0.481 0.544 -0.063 1.76E-05 0.0561 
4 cg14054990 KRTAP19-5 promoter 0.431 0.482 -0.052 1.84E-05 0.0565 
5 cg21049302 None intergenic 0.466 0.522 -0.056 1.98E-05 0.0565 
6 cg17022548 NRG2 intragenic 0.204 0.258 -0.054 1.99E-05 0.0565 
7 cg22472360 TRIO intragenic 0.514 0.569 -0.055 2.09E-05 0.0569 
8 cg07920414 RIMS3 intragenic 0.438 0.493 -0.055 2.18E-05 0.0572 
9 cg04088338 None intergenic 0.378 0.429 -0.051 2.54E-05 0.0590 
10 cg12240358 HOMER2 intragenic 0.462 0.519 -0.057 2.68E-05 0.0590 
11 cg09712306 AURKA intragenic 0.602 0.660 -0.058 3.48E-05 0.0605 
12 cg07939743 None intergenic 0.289 0.341 -0.052 3.50E-05 0.0605 
13 cg00803692 CCR5 promoter 0.370 0.424 -0.054 3.73E-05 0.0620 
14 cg10177030 SNORD12 three_plus 0.419 0.472 -0.053 3.85E-05 0.0627 
15 cg15439110 None intergenic 0.444 0.525 -0.080 3.93E-05 0.0628 
16 cg20385229 SLIRP intragenic 0.392 0.444 -0.052 4.13E-05 0.0628 
17 cg02393640 LUZP6 intragenic 0.390 0.443 -0.052 5.63E-05 0.0668 
18 cg17863551 CD177 promoter 0.419 0.478 -0.059 6.27E-05 0.0670 
19 cg15279541 None intergenic 0.388 0.439 -0.051 7.14E-05 0.0677 
20 cg20171999 RRS1 three_plus 0.403 0.474 -0.070 8.93E-05 0.0680 
21 cg20559385 None intergenic 0.428 0.479 -0.052 9.43E-05 0.0680 
22 cg21429780 MAML3 intragenic 0.493 0.545 -0.052 0.0001 0.0680 
23 cg01482790 HNRNPM intragenic 0.289 0.339 -0.050 0.0001 0.0681 
24 cg20684197 FGF1 intragenic 0.395 0.445 -0.051 0.0001 0.0684 
25 cg04279139 MANSC4 promoter 0.410 0.461 -0.051 0.0001 0.0688 
26 cg16853860 PSMB9 intragenic 0.272 0.332 -0.060 0.0001 0.0696 
27 cg27062514 CTR9 intragenic 0.463 0.526 -0.064 0.0001 0.0721 
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# Probe ID Gene Region Average  
beta   
Patients (T1) 
Average  
beta  
Patients (T2) 
Δ-beta P-Value BH-
adjusted P-
Value 
28 cg09931909 MB21D1 intragenic 0.420 0.497 -0.077 0.0001 0.0735 
29 cg13340231 ZNF704 intragenic 0.528 0.583 -0.055 0.0002 0.0751 
30 cg10035831 RPTOR intragenic 0.446 0.503 -0.057 0.0002 0.0753 
31 cg13927756 MYO10 intragenic 0.468 0.524 -0.056 0.0002 0.0754 
32 cg08749576 None intergenic 0.627 0.684 -0.058 0.0002 0.0761 
33 cg15484808 RPS18 intragenic 0.480 0.534 -0.054 0.0002 0.0811 
34 cg12802876 None intergenic 0.359 0.418 -0.059 0.0002 0.0828 
35 cg03548415 None intergenic 0.422 0.473 -0.051 0.0003 0.0853 
36 cg20547015 PPP1CC intragenic 0.453 0.517 -0.064 0.0003 0.0862 
37 cg23214895 None intergenic 0.569 0.620 -0.051 0.0003 0.0878 
38 cg12478092 CCDC116 promoter 0.510 0.573 -0.063 0.0003 0.0879 
39 cg15683542 MIPEP intragenic 0.694 0.747 -0.053 0.0003 0.0883 
40 cg09514545 MIR525 three_plus 0.442 0.501 -0.060 0.0004 0.0908 
41 cg01789743 NID1 intragenic 0.499 0.552 -0.053 0.0004 0.0910 
42 cg18524114 None intergenic 0.339 0.389 -0.050 0.0005 0.0933 
43 cg04410448 ZC2HC1B intragenic 0.491 0.541 -0.051 0.0005 0.0949 
44 cg13714407 RAPGEF1 intragenic 0.367 0.426 -0.059 0.0005 0.0953 
45 cg27367066 None intergenic 0.455 0.510 -0.054 0.0006 0.0967 
46 cg26837708 YBX1 intragenic 0.388 0.445 -0.058 0.0006 0.0967 
47 cg14817867 PRPSAP2 intragenic 0.419 0.471 -0.052 0.0006 0.0971 
48 cg13598358 PPP1CC intragenic 0.362 0.418 -0.056 0.0006 0.0978 
Abbreviations:  Average beta, mean methylation values (%); Benjamini-Hochberg (BH) adjusted P-value. 
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Supplementary Figure S3. Correlations between 450K array and pyrosequencing 
measures. a) Bland-Altman plots for verified CpGs show a slightly biased agreement 
between 450K dataset and pyrosequencing measures. b) Strong positive correlation 
between 450K and pyrosequencing measures for cg07280807 (Spearman rs = 0.85,  
P = 2E-16), cg18752527 (rs = 0.71, P = 3E-12), cg16529483 (rs = 0.79, P = 4E-16) and 
cg24496423 (rs = 0.80, P = 2E-16). 
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Supplementary Figure S4. Blood cell type associations of 3 examined CpG sites. a) 
DNA methylation of cg18752527 in the HECW2 gene was significantly associated with CD4+ 
and CD8+ T cells, along with NK cells, as determined by differential DNAm testing using a 
previous 450K dataset of purified blood cell types17 (P = 7.6E-15, ANOVA). DNA methylation 
of cg16529483 (b) and cg24496423 (c) in the SRPK3 gene were not significantly associated 
with any cell type (P > 0.6, ANOVA). 
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 Supplementary Table S4. Primers and PCR programs for validation and replication. 
cg07280807 (intergenic) 
fwd: 5’-GTTATGGTTGGGTTTTTGGG-3’ 
rev: 5’-Bio-CCTATCTCCTCAAACAAAAACTAAAAA-3’ 
seq: 5’-AGTTAGGGATTATAGTGTAGTTG-3’ 
Amplicon length: 156 bp 
 
coordinates: chr14:70,317,178-70,317,333 
 
Note: The amplicon contains 3 CpG sites, of which the third is 
cg07280807 
 
PCR program: 
95°C – 15 min 
------------------- 
45 cycles: 
94°C – 30 sec 
50°C – 30 sec 
72°C – 30 sec 
------------------- 
72°C – 10 min 
4°C – hold 
 
cg18752527 (HECW2) 
fwd: 5’-GTGTTTGTGGGAATGTTTTTTATA-3’ 
rev: 5’-Bio- CACACTACACTTTCATTTTCTATCAA-3’ 
seq: 5’- TTTTTAGATATATAAATTTTTTTTTT-3’ 
Amplicon length: 135 bp 
 
coordinates: chr2:197,132,798-197,132,932 
PCR program: 
95°C – 15 min 
------------------- 
45 cycles: 
94°C – 30 sec 
50°C – 30 sec 
72°C – 30 sec 
------------------- 
72°C – 10 min 
4°C – hold 
 
cg16529483 / cg24496423 (SRPK3) 
fwd/seq: 5’-GTTATTTATAAAGGAGGGTGAGATTA-3’ 
rev: 5’-Bio-AACCACTACTCCTATAAAACCCCAC-3’ 
Amplicon length: 85 bp 
 
coordinates: chrX:153,046,424-153,046,508 
 
Note: The amplicon contains 5 CpG sites, of which the first is 
cg16529483 and the fourth is cg24496423. Due to CpG sites 
in the primer binding area, the primers contain 1 (fwd) and 2 
(rev) mismatches, which are highlighted underlined. 
PCR program: 
95°C – 15 min 
------------------- 
45 cycles: 
94°C – 30 sec 
48°C – 30 sec 
72°C – 30 sec 
------------------- 
72°C – 10 min 
4°C – hold 
Abbreviations: fwd, forward primer; rev, reverse primer; seq, sequencing primer; Bio, 
biotin-modification; bp, basepair. 
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Abstract 
Borderline personality disorder (BPD) is a severe and complex mental disease 
associated with high suicidal tendencies and hospitalization rates. Accumulating 
evidence suggests that epigenetic mechanisms are implicated in the etiology of BPD. 
A recent epigenome-wide study identified several novel genes, which are 
epigenetically dysregulated in BPD. Those genes include APBA3, MCF2 and NINJ2. 
Psychotherapy such as Dialectical Behavior Therapy (DBT), an established treatment 
for BPD, provides an excellent setting to investigate environmental influences on 
epigenetic mechanisms in order to identify biomarkers for disease status and therapy 
success. However, the effects of DBT on epigenetic regulation have only been 
researched in one previous study analyzing BDNF. In the present study we aimed to 
investigate the role of DNA methylation of APBA3, MCF2 and NINJ2 as possible 
biomarkers for treatment-outcome in BPD, whilst validating the previous findings of 
differential DNA methylation in a cohort of 44 BPD patients and 44 well matched 
healthy control individuals. 
Unexpectedly, we did not detect significant DNA methylation differences between 
patients and control individuals. However, we found a high correlation between the 
methylation status of APBA3 and MCF2 and therapy outcome: before DBT treatment, 
both genes were significantly higher methylated in patients responding to therapy 
compared to patients that did not respond. 
Our study is the first to report results pointing to possible predictive epigenetic 
biomarkers of DBT outcome in BPD patients. Following replication in independent 
cohorts our finding could facilitate the development of more personalized therapy 
concepts for BPD patients by including epigenetic information. 
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Introduction 
With a prevalence of up to 2% in the general population and up to 25% in clinical 
settings, borderline personality disorder (BPD) is one of the most frequent personality 
disorders (Gunderson, 2009; Torgersen et al., 2001). A high rate of committed 
suicides (about 10% of the patients) characterizes the severity of this disease. In 
addition to the high rate of completed suicides, more than 70% of patients suffering 
from BPD had at least one suicide attempt in their medical history (Oldham, 2006). 
BPD is characterized by impairments in emotion and affect regulation, self-perception 
and interpersonal relationships. The severity of BPD is emphasized by the high rates 
of relapse after initial successful therapy observed in several short- and long-term 
studies (Gunderson, 2009; Leichsenring et al., 2011; Zanarini et al., 2006). This 
renders a sustainable therapy even more essential for a good prognosis. 
Dialectical behavior therapy (DBT) established by M. Linehan, is a widely-used 
psychotherapeutic treatment for BPD, whose efficacy has been shown in many 
studies (Bohus et al., 2004; Bohus et al., 2000; Linehan, 1993; William D. Barley, 
1993). Designed for suicidal patients meeting the BPD criteria, the main aim of the 
therapy is to reduce suicidal tendencies, including self-harmful behavior, as well as 
behavior preventing therapy or prolonging inpatient treatment (Bohus et al., 2004; 
Fleischhaker et al., 2011). Initially designed as outpatient treatment, the DBT was 
recently modified for inpatient settings, now typically lasting 12 weeks in European 
psychiatric institutions (Bohus et al., 2004). 
The pathomechanism of BPD is not completely understood to date. M. Linehans’ 
model of a biosocial development suggests that BPD is a disorder resulting from 
biological vulnerability combined with harming environmental influences. A 
depreciating and emotionally unstable environment during childhood together with 
genetic vulnerability could result in the disturbances of emotion regulation which is 
typical for BPD (Crowell et al., 2009; Linehan, 1993). Whereas twin and family 
studies suggest a heritability of BPD between 35 and 65% (Distel et al., 2009; 
Torgersen et al., 2000), individual risk genes could not be identified for BPD thus far 
(Calati et al., 2013; Gunderson, 2009). Over the past years, evidence emerged that 
epigenetic mechanism play a major role in the mediation of genome-environment-
interactions. Alterations in epigenetic regulation have been described for several 
psychiatric disorders e.g. major depression, schizophrenia and BPD (Januar et al., 
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2015; Perroud et al., 2016; Rivollier et al., 2014; Teschler et al., 2016). Epigenetics 
include posttranslational histone modifications, DNA methylation and the activity of 
non-coding RNAs (Hashimoto et al., 2010; Nieratschker et al., 2013). DNA 
methylation is catalyzed by methyltransferases (DNMTs) (Egger et al., 2004; Jones 
and Takai, 2001), which transfer a methyl group from S-adenosyl-methionine to 
cytosine creating 5-methyl-cytosine (Sutherland and Costa, 2003). Regulatory DNA 
methylation mainly occurs at the cytosine of a CpG dinucleotide. Whereas CpG sites 
are underrepresented throughout the genome, they are enriched in so called CpG 
islands (Jones and Takai, 2001), areas containing more than 50% of cytosine and 
guanine (Egger et al., 2004; Sutherland and Costa, 2003). CpG islands overlap with 
the promoter regions of 50 - 60% of human genes (Nieratschker et al., 2013) and are 
typically less methylated than CpG sites outside of CpG islands (Wang and Leung, 
2004). Hypermethylation of these regions usually inhibits transcription through 
several mechanisms (Sutherland and Costa, 2003). The epigenome was formerly 
believed to be stable after the embryonal development (Nieratschker et al., 2013; 
Razin and Riggs, 1980). However, current studies imply that epigenetic regulation is 
a more dynamic process that is influenced by environmental factors not only prenatal, 
but also postnatal (Jones and Takai, 2001; Nieratschker et al., 2014). 
Epigenetic research in BPD thus far has mainly focused on candidate genes of other 
psychiatric disorders e.g. BDNF, COMT, 5-HTT and MAOA (Dammann et al., 2011; 
Perroud et al., 2013; Teschler et al., 2013; Teschler et al., 2016). However, Teschler 
et al. investigated DNA methylation in BDP using a systematic epigenome-wide 
approach. In this previous study, 259 significantly differentially methylated CpG sites 
were discovered. The authors selected several of those sites for validation and where 
able to confirm their findings for three CpG sites located in APBA3 and one site in 
MCF2 and NINJ2, respectively (Teschler et al., 2013). An association with BPD has 
not been described for any of those genes before.  
An influence of psychotherapy on DNA methylation levels has been described 
recently. Roberts et al. found significant alterations in DNA methylation levels of the 
serotonin transporter gene (5-HTT) in the course of anxiety treatment in children 
(Roberts et al., 2014): Those who responded to cognitive behavior therapy (CBT) 
showed increased methylation levels at a specific CpG site after treatment, whereas 
the levels of non-responders decreased significantly. A second study reported similar 
results for FKBP5: Here, a decrease in DNA methylation during therapy was 
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associated with a strong reduction in symptom severity, whereas an increase in DNA 
methylation was associated with a weaker response to treatment (Roberts et al., 
2015). In addition to the findings in children suffering from anxiety disorder, an 
epigenetic effect of CBT has also been described in adult anxiety patients: Ziegler et 
al. detected epigenetic alterations in MAOA associated with response to CBT in adult 
panic disorder patients (Ziegler et al., 2016). Prior to therapy the DNA methylation 
levels of MAOA were significantly reduced in patients compared to healthy controls. 
While the DNA methylation levels of responders increased and where no longer 
significantly different from those of control individuals, the DNA methylation levels of 
non-responders decreased even further during the course of the CBT (Ziegler et al., 
2016). A similar correlation has been described for FKBP5 in the context of PTSD: 
While therapy responders showed a decrease, non-responders showed an increase 
in DNA methylation over time (Yehuda et al., 2013). In contrast to those findings, 
DNA methylation of GR was not significantly different in responders and non-
responders post-treatment, but the pre-treatment DNA methylation levels predicted 
treatment response to the extent that responders showed higher levels compared to 
non-responders (Yehuda et al., 2013). Only one study thus far investigated the 
epigenetic effects of DBT in BPD: Perroud et al. showed that BDNF DNA methylation 
levels decreased during treatment in therapy responders, but increased in non-
responders (Perroud et al., 2013). 
The aim of the present study was to investigate differential DNA methylation of 
APBA3, MCF2 and NINJ2 (Teschler et al., 2013) as potential epigenetic biomarker 
for treatment outcome in BPD. In addition, our study was designed to validate the 
previous findings on differential methylation of those genes and to identify potential 
influences of the DBT on DNA methylation patterns. Our study included 44 patients 
and 44 age, as well as gender matched control individuals. In the patient group, DNA 
methylation analyses were performed pre-treatment and were repeated at the end of 
the DBT program.  
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Experimental procedures 
Subjects 
The sample was comprised of 44 BPD patients (37 females and 7 males, mean age 
29.5 ± 8.4 years) hospitalized for a 12-week DBT program and 44 age and gender 
matched control individuals (37 females and 7 males, mean age 29.7 ± 8.8 years). 
Patients with a diagnosis of BPD according to the International Personality Disorder 
Examination (IPDE) and who met at least five diagnostic criteria of the fourth edition 
of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) were included 
in the study. Only control individuals with no psychiatric history were accepted in this 
study.  
Phenotypic information about patients and control individuals was obtained by self-
administered questionnaires. The following questionnaires were used: SCL90R 
(Franke, 2002), BSL23 (Wolf et al., 2009) and the childhood trauma questionnaire 
(CTQ) (Bernstein et al., 2003). All subjects were Caucasian and provided written 
informed consent prior to participation. The criteria for a BPD diagnosis are identity 
disturbance (present in 70.5% of our patients), unstable interpersonal relationships 
(90.9%), chronic feelings of emptiness (86.4%), efforts to avoid real or imagined 
abandonment (54.6%), affective instability (86.4%), inappropriate anger (77.3%), 
paranoid or dissociative symptoms (70.5%), impulsivity (86.4%) and self-harmful or 
suicidal behavior (88.6%). Patients reached an average of 2.42 points in the BSL23, 
which is considerably higher than the average score described in previous studies 
(Bohus et al., 2009; Wolf et al., 2009). The average t-score of the GSI was 79 points 
in patients. Control individuals reached a t-score of 44.7 and a BSL 23 score of 0.22, 
values indicating the absence of mental / psychological stress. 
Therapy responders are usually defined by reduction of self-harmful behavior. Since 
information about changes in self-harmful behavior through therapy was not available 
for our cohort, we chose a combination of two parameters that display the overall 
psychical burden and well-being of the patients for the classification of responders 
and non-responders, namely the global severity index (GSI) derived from the 
symptom checklist 90 (SCL90) and the borderline symptom list 23 (BSL23), 
developed especially for the severity of the borderline personality disorder. A patient 
was defined as responder if the GSI t-score was reduced by more than 5 points post-
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therapy and additionally a score lower than 2.05 for the BSL23 was reached. 
Applying this classification resulted in 7 responders and 17 non-responders. 
The study was approved by the ethics committee of the University of Tuebingen and 
was conducted in accordance with the Declaration of Helsinki.  
DNA methylation analysis 
Ethylenediaminetetraacetic (EDTA) peripheral venous blood samples were taken 
from all patients within the first week of hospital admission (T1). During the last week 
of the 12-week DBT-program (T2), a second EDTA-blood sample was taken from the 
24 patients (mean age 30.75 ± 8.81 years) completing therapy. EDTA-blood from 
control individuals was drawn immediately after study inclusion. Blood samples were 
instantly frozen and kept at -80°C until further usage. 
DNA extraction was performed using the QIAamp DNA Blood Maxi-Kit (Qiagen, 
Hilden, Germany). 500 ng of genomic DNA was bisulfite converted using the EpiTect 
Fast Bisulfite Conversion Kit (Qiagen) according to manufacturer’s protocol. PCR 
amplification and pyrosequencing was performed as described in Teschler et al 
(Teschler et al., 2013) with slight modifications. Primer (Eurofins Genomics, 
Ebersberg, Germany) sequences as well as cycling conditions are displayed in Table 
1. For APBA3 a nested PCR was performed. PCR products and a no template 
control were visualized on an agarose gel to verify successful amplification and 
specificity of the products. 
 
 
 
Table 1: PCR conditions and primers used 
Primer Sequence PCR-Program 
APBA3BSU1 5´-ATTTTAGTTTGGGTGATAGAGTGAGGTTT 95°C 
94°C 
49°C 
72°C 
72°C 
8°C 
15min 
30s 
30s 
30s 
10min 
storage 
APBA3BSL1 5´-BIO-CCTATATAAACAATACCCAACTAAAACCTAA 
 
 
 
(45 cycles, PCR-MasterMix QIAGEN) 
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APBA3BSU11 5´-GAGGTTTTGTTTTAAAAAAAATAAATAAATT 95°C 
94°C 
45°C 
72°C 
72°C 
8°C 
15 min 
30s 
30s 
30s 
10min 
storage 
APBA3BSL1 5´-BIO-CCTATATAAACAATACCCAACTAAAACCTAA 
APBA3BSSeq 5´-TTYGAAAAATAAAAAATTTGAGGTTT 
  
(45 cycles, PCR-MasterMix QIAGEN) 
MCF2BSU1 5’-GGGTAGGAYGAGAGTAAAAAGTATGAGTT 95°C 
95°C 
48,5°C 
72°C 
72°C 
8°C 
2min 
30s 
30s 
30s 
10min 
storage 
MCF2BSL1 5’-BIO-CAACTCTCTTCCTAAAAACAAACTTAATAAA 
MCF2BSSeq 5’-TTTATAAAGATTTTTAGTATTTTATTTTAAA 
 
 
 
(45 cycles, GoTaq-MasterMix Promega) 
NINJ2BSU4 5’-TTTATAYGTGTGTGTAGGTGTATATTTTTTT 95°C 
94°C 
47°C 
72°C 
72°C 
8°C 
15min 
30s 
30s 
30s 
10min 
storage 
NINJ2BSL2 5'-BIO-AAACAAACTACRTAAACTCCTCCAAA 
NINJ2BSSeq 5’-GTGTGTGTAGGTGTATATTTTTTTTAGAGG 
  
(45 cycles, PCR-MasterMix QIAGEN) 
 
Processing of the PCR amplicons for the pyrosequencing analysis was performed 
according to the manufacturer’s protocol and PCR products were then 
pyrosequenced using the PyroMark Q24 system and the PyroMark GoldReagents 
(Qiagen). To detect potentially biased amplification of differentially methylated 
fragments, DNA samples with known methylation levels (0%, 25%, 50%, 75% and 
100%) were included as controls (EpiTect Control DNA, Qiagen) in the amplification 
and the pyrosequencing analysis.  
The percentage of methylation at each of the three CpG sites analyzed was 
quantified using the PyroMark Q24 software version 2.0.6 (Qiagen). Pyrosequencing 
was performed in triplicates. To avoid batch effects, samples from patients and 
control individuals were mixed on each plate and the samples were randomly 
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assigned to different wells for each sequencing run. Only runs differing less than 3% 
were included in the analysis.  
Statistical analyses 
Statistical analysis was performed using SPSS Statistics Version 21 (IBM, NY, USA). 
DNA methylation levels of APBA3 were normally distributed according to the Shapiro-
Wilk test. T-tests for either independent or paired samples (for comparing T1 and T2) 
were applied. 
For MCF2, DNA methylation levels were not normally distributed according to the 
Shapiro-Wilk test. Hence, non-parametric test methods were applied. Significance 
level was set as alpha <0.05. 
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Results 
No difference in APBA3 and MCF2 DNA methylation status between patients at 
the beginning of the DBT program (T1) and control individuals  
For APBA3 two CpG sites were analyzed. The mean DNA methylation value of 
patients (n = 44, mean age 29.5 ± 8.4 years) was 83.7% for site 1 and 75.2% for site 
2, overall DNA methylation was 79.5%. The mean DNA methylation value of control 
individuals (n = 44, mean age 29.7 ± 8.8 years) was 82.7% (site 1) and 74.5% (site 
2), resulting in an overall DNA methylation value of 78.6%. This difference between 
patients and control individuals was not significant (independent samples t-test; site 
1: t = 1.0 p = 0.3; site 2: t = 0.6, p = 0.5; overall DNA methylation: t = 0.8, p = 0.4). 
For MCF2 one CpG site was analyzed. The mean DNA methylation value of this CpG 
site was 47.2% in patients and 50.2% in control individuals – this difference was not 
significant (Mann-Whitney U-Test: Z = -1.0, p = 0.3). 
Due to technical difficulties, NINJ2 was not included in further analysis. 
No effects of DBT on the DNA methylation status of APBA3 and MCF2  
When comparing patients completing the 12 weeks of therapy before and after 
treatment (n = 24, mean age 30.8 ± 8.8), DBT had no significant influence on the 
DNA methylation levels of either gene. Mean DNA methylation of APBA3 before 
therapy was 78.8%, for site 1, 83.2% and for site 2 74.4%. After completion of 
therapy DNA methylation was 78.4%, 82.6% and 74.1%, respectively (paired 
samples t-test; overall: t = 0.5, p = 0.6, site 1: t = 0.7, p = 0.5; site 2: t = 0.3, p = 0.8). 
For MCF 2 DNA methylation was 46.9% prior to therapy and 47.9% post-therapy 
(paired samples t-test; t = -0.010, p = 1.0). 
Therapy responders show increased pre-treatment DNA methylation levels (T1) 
Comparison of the DNA methylation status of APBA3 before and after therapy shows 
that therapy responders display significantly higher overall DNA methylation values 
prior to therapy than non-responders. The overall methylation value of responders 
was 81.5%, the value of non-responders 77.7% (independent samples t-test: t = -2.1, 
p = 0.044, Figure 1).  
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 Figure 1: Boxplot comparing overall DNA methylation values for APBA3 prior to therapy (T1) 
of non-responders and responders. * p ≤ 0.05. 
For MCF2 the same relationship between DNA methylation and therapy outcome 
applied: Patients responding to therapy showed significantly higher DNA methylation 
prior to treatment (T1). DNA methylation values of responders were 56.2%, non-
responders displayed DNA methylation values of 43.3% (Wilcoxon U-test: U = -2.8,  
p = 0.003; Figure 2). 
 
Figure 2: Boxplot comparing DNA methylation values for MCF2 prior to therapy (T1) of non-
responders and responders. ** p ≤ 0.01. 
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Moreover, an inverse correlation between the GSI t-score and DNA methylation of 
MCF2 before therapy was found: The higher the DNA methylation prior to treatment 
(T1), the lower the overall GSI t-score post-therapy (T2; Pearson correlation r = -0.4, 
p = 0.038). 
At T2, no significantly different DNA methylation levels between responding or non-
responding patients were detected for either gene. For APBA3 DNA methylation 
values were 77.8% for responders and 79.8% for non-responders (independent 
samples t-test: t = -1.0, p = 0.3). For MCF2 DNA methylation values of 48.9% for 
responders and 46.2% for non-responders were detected (Mann-Whitney U-test:  
U = -0.2, p = 0.9). 
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Discussion 
In the present study, we aimed to replicate the differential DNA methylation of APBA3 
and MCF2 in BPD patients compared to healthy control individuals described in a 
previous study (Teschler et al., 2013), but found no significant differences between 
the two groups. Furthermore, we did not detect a significant influence of DBT on the 
DNA methylation profile of these genes in our overall patient sample. However, 
APBA3 and MCF2 were found to be significantly hypermethylated at the beginning of 
treatment in individuals responding to DBT compared to non-responders, supporting 
the hypothesis that DNA methylation of APBA3 and MCF2 could serve as an 
epigenetic biomarker with predictive value for therapy outcome.  
Replication of epigenome-wide findings in independent cohorts is generally 
hampered by the high probability of type 1 errors, also referred to as false-positive 
results, in high-throughput experiments. This might explain why we were unable to 
detect DNA methylation differences in the analyzed candidate genes in our cohort 
although Teschler et al. supported their results by validation of some of their findings 
– including APBA3 and MCF2 – using an independent method, namely 
pyrosequencing. As one of the major drivers for differential DNA methylation is tissue 
or cell type (Jaffe and Irizarry, 2014), a second possible explanation for the non-
replication is the use of whole blood samples in both studies and the missing 
correction for blood-cell type composition. Other individual factors influencing DNA 
methylation are sex, age and health status (Farre et al., 2015; Jaffe and Irizarry, 
2014; Liu et al., 2010). To circumvent the issue of confounding factors, we matched 
our samples of patients and control individuals for age and sex to be able to 
investigate the influence of the individual’s health status (BPD vs. healthy control) on 
the DNA methylation pattern of the selected genes. Nevertheless, differences in 
blood-cell type composition between our samples and the samples analyzed by 
Teschler et al. could have prevented us from confirming their findings. 
Unfortunately, we can neither confirm nor refute potential hypermethylation of NINJ2 
as we were not able to obtain pyrosequencing results in sufficient quality for this 
locus even though the PCR and sequencing reaction was performed following the 
protocol described previously (Teschler et al., 2013) with slight modifications. This 
could potentially be explained by differences in the devices used to run the PCR 
reaction or by differences in primer as well as polymerase quality due to deviating 
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manufacturing protocols. All our attempts to optimize the analyses protocol and 
obtain satisfying results failed. This is probably attributed to the rather long target 
region which spans 172 nucleotides and is therefore difficult to analyse by 
pyrosequencing.   
The two genes successfully analyzed in our study, APBA3 and MCF2, have not been 
investigated in the context of psychotherapy before. In contrast to our initial 
hypothesis, we did not detect a significant effect of the psychotherapeutic 
intervention on the DNA methylation status of those genes when analyzing the 
overall patient sample. However, after dividing our samples into responders and non-
responders, we found both genes to be significantly hypermethylated prior to DBT in 
therapy responders. This significant difference was no longer detectable post-
treatment. Moreover, treatment response for the individual subjects was predicted by 
the DNA methylation levels of the MCF2 gene prior to therapy, as the methylation 
levels at T1 were significantly inversely correlated with the overall psychological 
burden (GSI t-score) post-treatment (T2).  
That we and others (Roberts et al., 2015; Roberts et al., 2014; Yehuda et al., 2013; 
Ziegler et al., 2016) identified differential DNA methylation in responders compared to 
non-responders but did not find a general effect of psychotherapeutic treatment in the 
overall group is not surprising, as one would expect functional changes in 
neurobiological processes mainly in the group of patients benefiting from the 
therapeutic intervention. To the best of our knowledge, the only other predictive 
epigenetic marker for psychotherapeutic treatment outcome described thus far is the 
glucocorticoid receptor gene (GR) in the context of a psychotherapeutic intervention 
in PTSD (Yehuda et al., 2013). Similar to our findings, an epigenetic effect of the 
therapeutic intervention itself could not be observed. A recent study demonstrated 
that HPA axis reactivity is associated with treatment outcome in a psychotherapeutic 
setting for PTSD (Rauch et al., 2017). As the differential methylation of the GR 
influences the HPA axis this association could explain the differences in response to 
treatment (Tyrka et al., 2016; Yehuda et al., 2015). Whether the differential DNA 
methylation of APBA3 and MCF2 in treatment responders and non-responders is 
also associated with neurobiological alterations directly influencing therapy outcome 
remains unanswered and needs to be addressed in future studies. Only one study 
published thus far investigated the influence of DBT on DNA methylation levels. The 
authors demonstrated a decrease in BDNF DNA methylation levels in DBT 
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responders and an increase in non-responders, but this DNA methylation alteration 
was not of predictive value as methylation prior to therapy was not correlated with 
treatment outcome (Perroud et al., 2013). In contrast to the findings for BDNF, our 
finding of differential DNA methylation between therapy responders and non-
responders prior to DBT suggests that the DNA methylation levels of APBA3 and 
MCF2 could serve as a molecular predictor of therapy outcome in BPD.  
The role of APBA3 and MCF2 in BPD is unclear. APBA3 is a member of the amyloid 
beta precursor protein binding family, interacting with the amyloid precursor protein 
(APP) whose proteolysis generates beta amyloid (Aβ), the primary component of the 
amyloid plaques associated with Alzheimers’ disease (Csiszar et al., 2013; Sullivan 
et al., 2014). Moreover, APBA3 is known to be epigenetically altered in adenoma or 
gastrointestinal tumors (Kim et al., 2003; Rashid et al., 2001). A link between MCF2, 
a guanine nucleotide exchange factor, and schizophrenia as well as autism-spectrum 
disorders was reported previously (Piton et al., 2011). MCF2 is involved in neurite 
outgrowth (Piton et al., 2011) and alterations in neuronal development associated 
with genetic or epigenetic alterations could potentially explain the link between this 
gene and psychiatric diseases. Future functional studies are warranted to clarify the 
role of APBA3 and MCF2 in BPD.  
This study is the first to present results pointing towards possible predictive 
epigenetic biomarkers for therapy response in BPD. However, our study also has a 
few limitations. First, although we were able to almost double the number of patients 
compared to a previous study (Teschler et al., 2013) and include four times as many 
control individuals, our sample size was still relatively small. This is especially true for 
the group of therapy responders which included only seven individuals, owed to the 
strict criteria we applied for categorizing therapy responders. However, in previous 
epigenetic studies of psychotherapeutic interventions the number of therapy 
responders was comparable to our study (Yehuda et al., 2013; Ziegler et al., 2016). 
To qualify as therapy responder, the patients were required to achieve a GSI t-score 
which was reduced by more than 5 points post-therapy and in addition a BSL23 
score lower than 2.05 had to be reached. Prior to therapy the patients in our cohort 
achieved a BSL23 score of 2.42 which is considerably higher than the average score 
of 2.05 BPD patients reached in several previous studies (Bohus et al., 2009; Wolf et 
al., 2009). Therefore, a reduction in the BSL score to average levels was considered 
a therapy success. To confirm our results, replication in larger cohorts is required. A 
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second limitation is that we were not able to perform a follow-up assessment of our 
patient group beyond the 12 weeks of inpatient treatment. Without knowing the 
subsequent health status of that group at a later time point following therapy, we 
cannot answer the question whether DNA methylation of APBA3 and MCF2 prior to 
therapy could also serve as a biomarker for long-term treatment outcome. Third, our 
study lacks functional data, as we did not analyze gene expression levels of our 
candidate genes. However, Teschler et al. showed that DNA methylation levels of 
APBA3 correlated with gene expression levels in human cells (Teschler et al., 2013), 
suggesting that the DNA methylation differences we observed in our sample might 
also result in differential expression of the respective genes. Nevertheless, functional 
investigations should be included in future studies to reveal the distinct role of both 
genes in BPD.  
In conclusion, to the best of our knowledge, we report the first findings pointing 
towards predictive epigenetic biomarkers for a psychotherapeutic treatment outcome 
in BPD. Our findings contribute to a better understanding of the biological 
underpinnings of BPD. In addition, the use of predictive biomarkers for therapy 
response could facilitate the development of more personalized therapy concepts. 
However, replication in larger cohorts is required to confirm our findings.  
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